Targeted Review: Medications for Acute Migraine Treatment

Irene Worthington¹, Tamara Pringsheim³, Marek J. Gawel¹,²,⁸,⁹, Jonathan Gladstone¹,², Paul Cooper⁴, Esma Dilli⁵, Michel Aube⁶, Elizabeth Leroux⁷, Werner J. Becker³ on behalf of the Canadian Headache Society Acute Migraine Treatment Guideline Development Group

ABSTRACT: Objective: To assess the evidence base for drugs used for acute treatment of episodic migraine (headache on ≤ 14 days a month) in Canada. Methods: A detailed search strategy was employed to find relevant published clinical trials of drugs used in Canada for the acute treatment of migraine in adults. Primarily meta-analyses and systematic reviews were included. Where these were not available for a drug or were out of date, individual clinical trial reports were utilized. Only double-blind randomized clinical trials with placebo or active drug controls were included in the analysis. Recommendations and levels of evidence were graded according to the principles of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group, using a consensus group. Results: Eighteen acute migraine medications and two adjunctive medications were evaluated. Twelve acute medications received a strong recommendation with supporting high quality evidence for use in acute migraine therapy (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ASA, ibuprofen, naproxen sodium, diclofenac potassium, and acetaminophen). Four acute medications received a weak recommendation for use with low or moderate quality evidence (dihydroergotamine, ergotamine, codeine-containing combination analgesics, and tramadol-containing combination analgesics). Three of these medications were NOT recommended for routine use (ergotamine, and codeine- and tramadol-containing medications), and strong recommendations were made to avoid use of butorphanol and butalbital-containing medications. Both metoclopramide and domperidone received a strong recommendation for use with acute migraine attack medications where necessary. Conclusion: Our target review formulated recommendations for the available acute medications for migraine treatment according to the GRADE method. This should be helpful for practitioners who prescribe medications for acute migraine treatment.


Can J Neurol Sci. 2013; 40: Suppl. 3 - S10-S32
management. The objective of this section of the guideline is to assess the evidence base for drugs used for acute treatment of episodic migraine (headache on ≤ 14 days a month) in Canada.

**METHODOLOGY**

A targeted review of the literature as outlined below was completed to assess available evidence for acute migraine medications in adults. Only drugs available in Canada are included in the guideline. Appendix 1 provides more information on the development of this guideline. For further details on the general principles of acute medication use, please see Section 1 of this guideline. Section 3 provides treatment strategies for choosing a specific acute medication for an individual patient.

**Literature Search Strategy**

A MEDLINE search of the English language for migraine disorders and use of triptans, ergotamine, dihydroergotamine, analgesics, NSAIDs, and antiemetics was performed. Only randomized, controlled trials (RCTs) and meta-analyses/systematic reviews of acute migraine medications in adults (18 years-of-age and older) and available in Canada were included. The initial search was limited to the years 1996 - May 2006 (first Canadian migraine guidelines were published in 1997). The search was updated in May 2010, and again in May 2012.

The following terms were used:
- *exp. migraine disorders, and*
- *sumatriptan or almotriptan or eletriptan or naratriptan or rizatriptan or zolmitriptan or frovatriptan or “triptan”, or*
- *exp. anti-inflammatory agents, non-steroidal, or*
- *exp. aspirin, or acetaminophen, or exp. analgesics, or*
- *ergotamine or dihydroergotamine, or*
- *exp. barbiturates or butalbital, or*
- *metoclopramide or domperidone or dimenhydrinate or exp. antiemetics*
- *limits: human, adults (18 years-of-age and older), English, randomized controlled trial (RCT) or meta-analysis*

The Cochrane Collaboration® and EMBASE were also searched for systematic reviews/meta-analyses. Clinical trials of acute medications used in the emergency room (e.g., parenteral antiemetics) were excluded.

**Evaluating Efficacy of Acute Therapies (endpoints)**

Various endpoints to assess efficacy of acute therapies have been used in clinical trials. Primary endpoints include “headache response” and “pain-free”. “Headache response” (also called “pain relief” or “headache relief”) is defined as a decrease in headache intensity from moderate or severe to mild or none, evaluated at pre-specified time intervals (e.g., 1, 2 or 4 hours). This endpoint has been used in most clinical trials. A “pain-free” outcome (moderate or severe to none) can also be measured at pre-specified time intervals. This is a desirable endpoint, which is endorsed by the International Headache Society (IHS); however, many older trials did not use this endpoint. “Sustained pain-free” refers to the number (%) of patients who are pain-free at two hours, and remain pain-free over the next 22 hours (without additional acute medication). Headache recurrence refers to the re-emergence of a moderate or severe headache (generally within 24 hours) after an initial headache response.

Consistency of response refers to reproducible pain relief over several attacks. Other secondary outcomes include the ability to reduce associated symptoms of nausea, vomiting, photophobia and phonophobia. Reduction in clinical disability refers to the medication’s ability to reduce functional impairment due to pain and associated migraine symptoms. These outcomes may be measured within a single attack or across multiple attacks. The most important outcomes desired by patients are pain-free outcomes (two hour pain-free) and sustained pain-free over 24 hours.2

Comparison of acute migraine therapies is complicated by use of different outcome measures in different clinical trials. Debate continues about the best outcome measure in assessing a drug’s efficacy in acute migraine therapy. It should be noted that newer drugs (e.g., triptans) tend to have more RCTs and better trial methodology than older drugs (e.g., ergot derivatives); this may result in newer drugs being favoured over older ones.

**Criteria for Considering Studies for this Guideline**

Only RCTs and meta-analyses/systematic reviews of acute migraine medications in adults (English language) were included in this guideline. Due to the large number of placebo-controlled trials of individual triptans, meta-analyses/systematic reviews, if available, rather than individual RCTs were included. However, if no meta-analyses/systematic reviews were found for a particular drug, then RCTs were included. Clinical trials of acute medications in the emergency room setting or in pediatric patients were excluded.

**Methods of the Review**

Titles and abstracts of studies and meta-analyses identified by the literature search were screened for eligibility by two independent reviewers for the initial search (IW and MJG), for the second search (up to May 2010; IW and TP), and for the third search (2010 – May 2012; IW and WJB). Papers that could not be excluded with certainty on the basis of the information contained in the title or abstract were reviewed in full. Papers passing the initial screening process were retrieved and the full text was reviewed.

**Grading of Recommendations and Assessment of Overall Quality of Evidence**

The recommendations were graded based on the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group. Using the GRADE system, the strength of a recommendation reflects the extent to which we can be confident that the desirable effects of an intervention outweigh the undesirable effects. The strength of a recommendation in the GRADE system is based on several factors including:

1. The balance between the desirable and undesirable consequences of a therapy, for example, the balance between the benefits and the side effects of a drug.
2. The quality of the evidence on which judgements of the magnitude of the benefit and the potential harm of an intervention are based.
GRADE recommendations are made in two categories. A strong recommendation means that the intervention could be used for most patients, and that the benefits of therapy outweigh the potential risks. A weak recommendation indicates that the intervention could still be applied to a majority of patients, but it would not be appropriate for many. With a weak recommendation, the balance between risks and benefits is closer or more uncertain. In other words, whether the intervention is suitable for a patient depends a great deal on the clinical situation and the nature of the patient. For this reason, weak recommendations are sometimes called “conditional” recommendations, as whether they are appropriate depends (or is conditional) on the details of the clinical situation much more so than for a strong recommendation. The quality of evidence supporting the recommendation indicates how much confidence we have in that recommendation. The meaning of the various recommendation categories and their clinical implications are given in Table 2. As shown in Table 2, it is important to recognize that the recommendations as formulated in GRADE are somewhat dichotomous. If the benefits clearly outweigh the risks and burdens, a medication gets a strong recommendation, even though the evidence that the drug is effective may not be strong. Thus, for a drug with very few side effects, it is possible to have a strong recommendation coupled with low quality evidence (i.e., “Strong – low quality evidence”).

**ACUTE THERAPIES: EVIDENCE FOR EFFICACY**

**Migraine-Specific and Non-Specific Agents**

In 2002, a quantitative systematic review/meta-analysis (54 trials) of pharmacological treatments (triptans, dihydroergotamine, ASA plus metoclopramide) for acute migraine concluded that most interventions are effective. However, this review did not include NSAIDs or acetaminophen. Numbers-needed-to-treat (NNTs) were calculated. For headache relief at 2 hours (h), NNTs ranged from 2.0 for subcutaneous

---

**Table 1: Levels of evidence: GRADE system**

<table>
<thead>
<tr>
<th>Level of Evidence</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>High quality</td>
<td>We are confident that the true effect lies close to the estimate given by the evidence available.</td>
</tr>
<tr>
<td>Moderate quality</td>
<td>We are moderately confident in the effect estimate, but there is a possibility it is substantially different.</td>
</tr>
<tr>
<td>Low quality</td>
<td>Our confidence in the effect estimate is limited. The true effect may be substantially different.</td>
</tr>
<tr>
<td>Very low quality</td>
<td>We have little confidence in the effect estimate.</td>
</tr>
</tbody>
</table>

---

**Table 2: Recommendation grades: meaning and clinical implications**

<table>
<thead>
<tr>
<th>Recommendation Grade</th>
<th>Benefit versus Risks</th>
<th>Clinical Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong – high quality evidence</td>
<td>Benefits clearly outweigh risks and burden for most patients</td>
<td>Can apply to most patients in most circumstances</td>
</tr>
<tr>
<td>Strong – moderate quality evidence</td>
<td>Benefits clearly outweigh risks and burden for most patients</td>
<td>Can apply to most patients, but there is a chance the recommendations may change with more research</td>
</tr>
<tr>
<td>Strong – low quality evidence</td>
<td>Benefits clearly outweigh risks and burden for most patients</td>
<td>Can apply to most patients, but there is a good chance the recommendations could change with more research</td>
</tr>
<tr>
<td>Weak – high quality evidence</td>
<td>Benefits are more closely balanced with risks and burdens for many patients</td>
<td>Whether a medication is used will depend upon patient circumstances</td>
</tr>
<tr>
<td>Weak – moderate quality evidence</td>
<td>Benefits are more closely balanced with risks and burdens for many patients</td>
<td>Whether a medication is used will depend upon patient circumstances, but there is less certainty about when it should be used</td>
</tr>
<tr>
<td>Weak – low quality evidence</td>
<td>Benefits are more closely balanced with risks and burdens</td>
<td>There is considerable uncertainty about when to use this medication</td>
</tr>
</tbody>
</table>
sumatriptan 6 mg (most effective) to 5.4 for naratriptan 2.5 mg (least effective). For pain-free endpoint at 2 h, NNTs ranged from 2.0 for subcutaneous sumatriptan 6 mg (most effective) to 8.6 for ASA 900 mg plus metoclopramide 10 mg (least effective). For sustained relief endpoint over 24 hours (headache response at 2 h and no recurrence within 24 h), NNTs ranged from 2.8 for eletriptan 80 mg (most effective; not an approved dose in Canada) to 8.3 for rizatriptan 5 mg (least effective).

1. MIGRAINE-SPECIFIC AGENTS

Triptans (selective serotonin 5-HT1B/1D receptor agonists)

Overview

The triptans are serotonin (5HT) agonists that are relatively specific for the 5HT1B and 5HT1D receptors. Because of this specificity, they offer relatively good migraine relief for many patients, with fewer side effects than the older ergot derivatives. There are currently seven triptans available in Canada: almotriptan (oral tablet), eletriptan (oral tablet), frovatriptan (oral tablet), naratriptan (oral tablet), rizatriptan (oral tablet, orally disintegrating tablet), sumatriptan (subcutaneous injection, oral tablet, fast-disintegrating oral tablet, nasal spray), and zolmitriptan (oral tablet, orally disintegrating tablet, nasal spray). Triptans are vasoconstrictors and therefore, are contraindicated in patients with coronary and cerebrovascular disease, but have proven remarkably safe in patients without vascular disease.9-11 There has also been concern about serotonin syndrome, particularly when the triptans are used in association with other drugs that enhance serotonergic activity, but clinical experience indicates that serotonin syndrome must be extremely rare with triptan use, even in the presence of concomitant selective serotonin reuptake inhibitor (SSRI) use.12,13 Section 3 of the guideline discusses all these issues in more detail. A disadvantage of triptans is their relatively high cost compared to other acute therapies; however, generic versions of triptans are now available at a slightly lower cost.

There is no single, randomized, controlled trial comparing all of the triptans with each other. Most trials compare a triptan to placebo, and head-to-head trials usually compare sumatriptan with one other triptan. Therefore, meta-analyses and comprehensive reviews (e.g., Cochrane Database) must be used to compare efficacy among triptans.9

Meta-analyses/systematic reviews of triptans

A meta-analysis of 53 randomized, double-blind, controlled (placebo or active comparator) trials in adults published in 2002 concluded that all oral triptans are effective and well tolerated.14 This meta-analysis included published studies, as well as “raw patient data” provided by pharmaceutical companies. Rizatriptan 10 mg, eletriptan 80 mg (not an approved dose in Canada), and almotriptan 12.5 mg provided the highest likelihood of consistent success over multiple attacks (inpatient consistency; headache response and pain-free at 2h); however, sumatriptan featured the longest clinical experience and widest range of formulations. Rizatriptan 10 mg was superior to sumatriptan 100 mg in terms of efficacy (sustained pain freedom at 24 h) and consistency. Eletriptan 80 mg was superior to sumatriptan 100 mg in terms of efficacy (pain relief at 2 h and sustained pain freedom at 24 h) but was associated with lower tolerability. Almotriptan 12.5 mg showed better sustained pain freedom compared to sumatriptan 100 mg, combined with good tolerability.14,15

A systematic review of double-blind, randomized, clinical trials of oral triptans reporting data after a single migraine attack was published in 2007; this analysis did not include raw data submitted by pharmaceutical companies, only published trials.16 The main objective was to compare the efficacy and tolerability of seven currently marketed oral, non-re-encapsulated triptan formulations (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan) versus placebo for the treatment of moderate-to-severe migraine attacks. Out of 221 publications reviewed, 38 studies were included in the analysis. All of the triptans provided significant relief (i.e., headache response) and/or absence of pain at 2 h (i.e., pain-free), as well as relief of pain (i.e., headache response) at 1 h, when compared with placebo. After 30 minutes, rizatriptan 10 mg (regular and orally disintegrating tablets), sumatriptan 50 and 100 mg (fast dissolving tablets), and sumatriptan 50 mg (regular tablets) showed significant headache response compared to placebo; fast-dissolving sumatriptan 100 mg was the only oral triptan that was superior to placebo for the pain-free endpoint at 30 minutes. Eletriptan 40 mg and fast-dissolving sumatriptan 50 mg and 100 mg showed a lower rate of recurrence than placebo at 24 hours, whereas rizatriptan 10 mg tablets showed a greater rate of recurrence than placebo.

Another systematic review was undertaken to consolidate evidence concerning safety and efficacy of triptans available in Canada at the time of publication in 2001 (sumatriptan, rizatriptan, naratriptan, zolmitriptan), and to provide guidelines for selection of a triptan.17 Data from published, randomized, placebo-controlled trials were pooled. A combined number need to treat (NNT) and number needed to harm (NNH) was generated for each triptan. The lowest NNT (highest efficacy) for headache response/pain-free at 2 h was observed with subcutaneous sumatriptan. Among the oral triptans, the lowest NNT was observed with rizatriptan (highest efficacy), and the highest NNT with naratriptan (lowest efficacy). The lowest NNH (i.e., most harm) was seen with subcutaneous sumatriptan. Rizatriptan appeared to provide earlier and better relief of migraine-associated nausea than the other oral triptans (i.e., naratriptan, sumatriptan, zolmitriptan). The authors concluded that all of the currently available triptans are effective symptomatic medications for acute migraine attacks. Sumatriptan had the most extensive data supporting its efficacy, tolerability, and safety; however, the newer triptans have some advantages over sumatriptan. Although there are differences among the triptans, they appear to be relatively small.17

Individual triptan meta-analyses (see Table 3)

Individual meta-analyses have been published for the following triptans: sumatriptan (oral, subcutaneous, intranasal), naratriptan, frovatriptan, almotriptan, and zolmitriptan.

Triptans versus triptans (see Table 4)

There are relatively few randomized, controlled, head-to-head trials comparing triptans to each other. Most head-to-head trials compare oral sumatriptan to one of the other triptans, and have utilized the 2-h headache response as a primary efficacy
measure (2 h pain-free response is a preferred endpoint in clinical trials).9

Although all seven triptans available in Canada show significant efficacy and good tolerability, and the differences between them are relatively small, head-to-head trials do support the presence of some differences. Unfortunately, comparison trials do not exist for all the triptans, and there are concerns that the results of some of them may have been affected by encapsulation. Based on available trials, it is possible to draw some conclusions, recognizing that the response of the individual patient to a specific triptan cannot be predicted, and as has often been said, the differences among patients appear greater than the differences among the triptans themselves. Rizatriptan (10 mg) does tend to provide faster headache relief compared to a number of other oral triptans, and better relief of nausea than sumatriptan. Eletriptan (40 mg) may show a greater sustained 24 hour response rate than sumatriptan, due at least in part to a relatively low headache recurrence rate. Almotriptan (12.5 mg) tends to show a lower adverse event rate than some other triptans (zolmitriptan and sumatriptan). Naratriptan and frovatriptan tend to have a slower onset of action and, therefore, a lower response rate at early time points after treatment, although in the direct comparison trials (see Table 4), frovatriptan (2.5 mg) appears to show similar efficacy at 2 h compared to several other triptans. These studies were relatively small with limited power to detect differences, however, and should therefore be interpreted with caution.

**Triptans versus ASA and NSAIDs** (see Table 5)

Overall, results of comparative trials have indicated that NSAIDs are generally as effective as triptans (see Acetylsalicylic acid and NSAIDs sections). However, experience in clinical practice suggests that oral triptans are superior to non-specific acute treatments in many patients (see “Triptans versus non-triptans: summary”).

**Triptans versus ergot derivatives**

Triptans have shown superior efficacy over ergotamine/caffeine in acute migraine (see Ergotamine section).

**Triptans versus non-triptans – summary**

There are relatively few randomized, controlled trials comparing triptans to other classes of acute migraine medications. Most of the trials compared sumatriptan to other drugs. In many of the trials, differences between triptans and other acute migraine medications on primary endpoints were not dramatic. In a review of published trials comparing oral triptans with non-triptans in 2004, Lipton et al found that data suggested a significantly greater benefit with triptans than ergotamine, but no significant difference between triptans and NSAIDs or other analgesics.18

However, experience in clinical practice suggests that oral triptans are superior to non-specific acute treatments in many patients. Thus, there appears to be a discrepancy between clinical trial results and clinical experience. Several explanations have been proposed for this discrepancy: statistically significant differences may not have been noted due to lack of adequate statistical power in clinical trials; patient selection, whereby patients treated with triptans in clinical practice may be relatively more responsive to triptans and less responsive to other agents than patients participating in clinical trials; headache response at 2 h, an endpoint in many clinical trials, may not fully capture the benefits of triptans relative to other agents, as assessed in clinical practice; waiting until pain is moderate or severe, as required in most clinical trials, may disadvantage triptans relative to comparators, whereas early treatment during mild pain may increase the benefit of triptans versus other classes of drugs.18

**Triptans combined with NSAIDs**

Since multiple peripheral and central neural mechanisms may be involved in migraine pathophysiology, drug combinations may potentially achieve better response rates than single drugs. A few studies have evaluated the efficacy of triptans combined with NSAIDs.

A multicentre, randomized, double-blind, double-dummy, placebo-controlled, four-arm study (n=972) evaluated the efficacy and tolerability of the combination of oral sumatriptan 50 mg (encapsulated) and naproxen sodium 500 mg (as two separate tablets).19 Patients treated a single moderate or severe migraine attack with placebo, naproxen sodium 500 mg, sumatriptan 50 mg, or a combination of sumatriptan 50 mg and naproxen sodium 500 mg; in the latter two treatment arms, sumatriptan tablets were encapsulated in order to achieve blinding of the study. The primary endpoint was 24-h “sustained pain response” (pain no greater than mild at 2 h post-dose, taking no rescue medications for 24 h post-dose, and having no recurrence of moderate or severe pain within 24 h of the initial dose). In the sumatriptan plus naproxen sodium group, 46% of subjects achieved a 24-h sustained pain response, which was significantly more effective than sumatriptan alone (29%), naproxen sodium alone (25%), or placebo (17%; p<0.001). There was no significant increase in the incidence of adverse effects with the combination compared to monotherapy with sumatriptan. Encapsulation of sumatriptan for blinding purposes may have altered its pharmacokinetic profile and thereby, possibly decreased efficacy responses.19

The superiority of fixed-combination sumatriptan/naproxen sodium (85/500 mg; not currently available in Canada) vs. sumatriptan 85 mg (monotherapy) or naproxen sodium 500 mg (monotherapy) was demonstrated in a publication reporting the results of two identically designed randomized, placebo-controlled trials (n=3413).20 In both studies, the fixed-combination resulted in a significantly higher 2-h headache relief rate (defined as pain reduction from moderate or severe to mild or no pain) than sumatriptan monotherapy (65% vs. 55%, respectively, p=0.009 in study 1; 57% vs. 50%, p=0.02 in study 2).

Two replicate, multicentre, randomized, double-blind, placebo-controlled, 2-attack, crossover trials (n=144, study 1; n=139, study 2) evaluated the efficacy of a fixed-dose formulation of sumatriptan 85 mg and naproxen sodium 500 mg (vs. placebo) in migraineurs who had discontinued treatment with a short-acting triptan in the past year because of poor response or intolerance (note: fixed-dose formulation is not available in Canada).21 Patients had discontinued an average of 3.3 triptans before study entry. Patients were instructed to treat
<table>
<thead>
<tr>
<th>Drug &amp; route (publication date)</th>
<th>Objective</th>
<th>Efficacy outcomes and main results</th>
<th>Conclusions and limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sumatriptan oral (2012)</td>
<td>To determine efficacy &amp; tolerability of oral sumatriptan vs. placebo &amp; other active interventions in treatment of acute migraine attacks in adults</td>
<td>Primary efficacy outcomes: pain-free at 1 h &amp; 2 h (no rescue medication); headache relief at 1 h &amp; 2 h; sustained pain-free during 24 h post-dose (pain-free at 2 h &amp; no use of rescue medication or recurrence of moderate to severe pain within 24 h); sustained headache relief during 24 h post-dose (headache relief at 2 h; sustained for 24 h with no use of rescue medication or second dose of study medication)</td>
<td>Oral sumatriptan is effective as an abortive treatment for acute migraine attacks, relieving pain, nausea, photophobia, phonophobia, &amp; functional disability, but is associated with increased AEs vs. placebo.</td>
</tr>
<tr>
<td>61 RCTs (24 vs. placebo only; 13 vs. active comparator only; 24 vs. placebo &amp; active comparator)</td>
<td>n=37,250</td>
<td>Direct comparisons with other active treatments: other triptans, acetaminophen, ASA, NSAIDs, &amp; ergotamine combinations</td>
<td>Results for 25 mg dose were similar to 50 mg dose, while 100 mg dose was significantly better than 50 mg for pain-free and headache relief at 2 h.</td>
</tr>
<tr>
<td>Types of participants: adults (≥ 18 years); IHS criteria for migraine diagnosis; stable prophylactic therapy allowed</td>
<td></td>
<td>Main results: For sumatriptan 50 mg vs. placebo: Pain-free at 2 h: 28% vs. 11% (NNT=6.1) Headache relief at 2 h: 57% vs. 32% (NNT=4.0) Sustained pain-free (24 h): 17% vs. 7% (NNT = 9.5)</td>
<td>Data support general guideline to use 50 mg as starting dose, with increases to 100 mg, if necessary &amp; tolerated (some patients may find a 25 mg dose is sufficient).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>For sumatriptan 100 mg vs. placebo: Pain-free at 2 h: 32% vs. 11% (NNT=4.7) Headache relief at 2 h: 64% vs. 32% (NNT=3.5) Sustained pain-free (24 h): 24% vs. 8% (NNT=6.5)</td>
<td>Treating early, during mild pain phase, gave significantly better NNTs for pain-free at 2 h and sustained pain-free at 24 h than did treating established attacks with moderate or severe pain intensity.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>For sumatriptan 50 mg vs. eletriptan 1,000 mg: Pain-free at 2 h: 32% vs. 26% (NS)</td>
<td>AEIs: mostly mild to moderate severity, self-limiting; clear dose response relationship (25 mg to 100 mg); serious AEIs uncommon</td>
</tr>
<tr>
<td></td>
<td></td>
<td>For sumatriptan 100 mg vs. ASA, 900 mg + metoclopramide: Pain-free at 2 h: 26% vs. 16%; NNT=10 in favour of sumatriptan</td>
<td>Limitations: most studies industry-sponsored using brand name; no generic sumatriptan trials found; limited data on sustained pain relief or pain-free (24 or 48 h); more early intervention studies needed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>For sumatriptan 50 mg vs. rizatriptan 10 mg: Pain-free at 2 h: 35% vs. 39% (NS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>For sumatriptan 100 mg vs. rizatriptan 10 mg: Pain-free at 2 h: 31% vs. 37%; NNT=16 in favour of rizatriptan</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>For sumatriptan 50 mg vs. eletriptan 40 mg: Pain-free at 2 h: 18% vs. 24%; NNT=16 in favour of eletriptan</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>For sumatriptan 100 mg vs. eletriptan 40 mg: Pain-free at 2 h: 24% vs. 32%; NNT=12 in favour of eletriptan</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>For sumatriptan 50 mg vs. almotriptan 12.5 mg: Pain-free at 2 h: 33% vs. 28% (NS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sumatriptan subcutaneous (SC) (2012)</td>
<td>To determine efficacy &amp; tolerability of SC sumatriptan vs. placebo &amp; other active interventions in treatment of acute migraine attacks in adults</td>
<td>Primary efficacy outcomes: pain-free at 1 h &amp; 2 h (no rescue medication); headache relief at 1 h &amp; 2 h; sustained pain-free during 24 h post-dose (pain-free at 2 h &amp; no use of rescue medication or recurrence of moderate to severe pain within 24 h); sustained headache relief during 24 h post-dose (headache relief at 2 h; sustained for 24 h with no use of rescue medication or second dose of study medication)</td>
<td>SC sumatriptan is an effective abortive treatment for acute migraine attacks, quickly relieving pain, nausea, photophobia, phonophobia, and functional disability, but is associated with increased AEIs vs. placebo.</td>
</tr>
<tr>
<td>35 RCTs (28 vs. placebo; 3 vs. active comparator only; 4 vs. placebo &amp; active comparator)</td>
<td>n=9365</td>
<td>Main results: For sumatriptan 6 mg SC vs. placebo: Pain-free at 2 h: 41% vs. 7% (NNT=2.9) Pain-free at 2 h: 59% vs. 15% (NNT=2.3) Headache relief at 1 h: 71% vs. 26% (NNT=2.2) Headache relief at 2 h: 79% vs. 31% (NNT=2.1) Sustained pain-free (24 h): 31% vs. 15% (NNT=6.1)</td>
<td>Most data is for 6 mg dose; data suggest a 4 mg dose (where available) may be a sensible starting dose, with increase to 6 mg, if response is inadequate &amp; higher dose is tolerated.</td>
</tr>
<tr>
<td>Types of participants: adults (≥ 18 years); IHS criteria for migraine diagnosis; stable prophylactic therapy allowed</td>
<td></td>
<td>Sumatriptan SC vs. active comparators [SC naratriptan (not available in Canada); IV ASA (not available in Canada); oral effervescent ASA + metoclopramide; IN &amp; SC DHE] – insufficient data for a pooled analysis</td>
<td>No evidence that taking second dose of sumatriptan 6 mg in event of inadequate response makes a difference.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AEIs: mostly mild to moderate – self-limiting; serious AEIs overall = 0.25%; for sumatriptan 6 mg vs. placebo: NNH=49</td>
<td>Limitations: insufficient evidence to address several important primary &amp; secondary outcomes (e.g., 24 h sustained efficacy; 1 h pain-free); lack of early interventions studies when pain is mild</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sumatriptan intranasal (IN) (2012)</td>
<td>To determine efficacy &amp; tolerability of IN sumatriptan compared to placebo &amp; other active interventions in the treatment of acute migraine attacks in adults</td>
<td>Primary efficacy outcomes: pain-free at 1 h &amp; 2 h (no rescue medication); headache relief at 1 h &amp; 2 h; sustained pain-free during 24 h post-dose (pain-free at 2 h &amp; no use of rescue medication or recurrence of moderate to severe pain within 24 h); sustained headache relief during 24 h post-dose (headache relief at 2 h; sustained for 24 h with no use of rescue medication or second dose of study medication)</td>
<td>IN sumatriptan is effective as an abortive treatment for acute migraine attacks, relieving pain, nausea, photophobia, phonophobia, &amp; functional disability, with single doses of 10 mg or more providing clinically useful levels of relief, but is associated with increased AEIs vs. placebo.</td>
</tr>
<tr>
<td>12 RCTs (10 vs. placebo only; 2 vs. active comparator)</td>
<td>n=4755</td>
<td>Main results: Sumatriptan 20 mg vs. placebo: Pain-free at 2 h: 32% vs. 11% (NNT=4.7) Headache relief at 1 h: 46% vs. 25% (NNT=4.9) Headache relief at 2 h: 61% vs. 32% (NNT=3.5)</td>
<td>Data suggest that a 10 mg dose may be a sensible starting dose (depending on availability; 5-mg and 20-mg strengths are available in Canada), with increase to 20 mg, if there is an inadequate response.</td>
</tr>
<tr>
<td>Types of participants: adults (≥ 18 years); IHS criteria for migraine diagnosis; stable prophylactic therapy allowed</td>
<td></td>
<td>Active comparators (2 trials): sumatriptan 20 mg IN vs. DHE 1 mg: no usable data; sumatriptan 20 mg IN vs. rizatriptan (ODT) 10 mg: rizatriptan had higher % headache relief at 2 h (71% vs. 65%) &amp; relief of associated symptoms at 2 h</td>
<td>AEIs: increased vs. placebo; most AEIs mild of short duration.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AEIs: mild to moderate severity, self-limiting; serious AEIs uncommon; taste disturbance significantly higher incidence for sumatriptan IN 10/20 mg vs. placebo (22.30% vs. 1%; NNH=3.5 &amp; 4.8, respectively)</td>
<td>Limitations: insufficient evidence to address several important primary &amp; secondary outcomes (e.g., 24 h sustained efficacy; 1 h pain-free); lack of early interventions studies when pain is mild</td>
</tr>
</tbody>
</table>
Table 3: Individual triptan meta-analyses [part 2] continued

<table>
<thead>
<tr>
<th>Triptan</th>
<th>Type of participants</th>
<th>Study design</th>
<th>Efficacy outcomes</th>
<th>NNT</th>
<th>Risk of AEs</th>
<th><strong>Tolerability</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Zolmitriptan oral, intranasal (2008)85</td>
<td>24 RCTs; n=15,408 (ages 12–65)</td>
<td>Types of participants: adults (18-65 years) and/or adolescents (12–17 years); IHS criteria for migraine diagnosis</td>
<td>To assess relative efficacy and tolerability of different formulations of zolmitriptan compared with placebo, active comparators, or different dosage forms of zolmitriptan in acute migraine attacks</td>
<td>Efficacy outcomes*: % of pts with: (1) headache relief at 1 h and 2 h post-dose; (2) pain-free at 1 h and 2 h post-dose; (3) sustained pain-free response over 24 h post-dose; Primary outcomes: headache relief and pain-free responses at 2 h post-dose</td>
<td>Results: All 3 formulations of zolmitriptan were significantly more effective vs. placebo for all efficacy outcomes. For 2-h pain-free rates: zolmitriptan 2.5 mg tablet was as effective as almotriptan 12.5 mg, eletriptan 40 mg, sumatriptan 50 &amp; 100 mg, and more effective than naratriptan 2.5 mg. Zolmitriptan 5 mg nasal spray had faster onset of action and greater efficacy vs. zolmitriptan 2.5 mg tablet. Zolmitriptan 2.5 mg had lower risks of AEs than eletriptan 80 mg, but higher risks than naratriptan 2.5 mg or rizatriptan 10 mg.</td>
<td>Zolmitriptan is an effective treatment for acute migraine attacks. For pain-free 2 h, zolmitriptan 2.5 mg tablet showed similar efficacy to almotriptan 12.5 mg, eletriptan 40 mg, and sumatriptan 50 mg, and greater efficacy vs. naratriptan 2.5 mg. Zolmitriptan 2.5 mg showed similar efficacy to rizatriptan 10 mg for headache relief and pain-free response, but was less effective for sustained pain-free response. Nasal spray (5 mg) had faster onset of action and greater efficacy vs. zolmitriptan 2.5 mg oral tablet.</td>
</tr>
<tr>
<td>Naratriptan oral (2004)86</td>
<td>10 RCTs (9 DB) n=4499 (ages 18-65)</td>
<td>Types of participants: adults (18-65 years); IHS criteria for migraine diagnosis</td>
<td>To evaluate comparative efficacy and tolerability of naratriptan in acute migraine attacks</td>
<td>Efficacy outcomes**: (1) headache relief at 2 h and 4 h post-dose; (2) pain-free at 2 h and 4 h post-dose; (3) sustained relief over 24 h</td>
<td>Results: Pooled RRs vs. placebo for pain-free response at 2 h and 4 h for naratriptan 2.5 mg: 2.52 (95% CI: 1.78-3.57), and 2.58 (95% CI: 1.99-3.35). Naratriptan 2.5 mg more effective vs. naratriptan 1 mg: RRs for pain-free response at 2 h and 4 h were 1.64 (95% CI: 1.28-2.06), and 1.35 (95% CI: 1.20-1.51). Naratriptan 2.5 mg less effective in pain-free response vs. rizatriptan 10 mg at 4 h (RR: 0.68; 95% CI: 0.55-0.85) or sumatriptan 100 mg at 4 h (RR: 0.79; 95% CI: 0.79-95% CI: 0.67-0.93). Significantly fewer pts had AEs with naratriptan 2.5 mg vs. rizatriptan 10 mg (RR: 0.73; 95% CI: 0.56-0.97) or sumatriptan 100 mg (RR: 0.68; 95% CI: 0.55-0.86).</td>
<td>Naratriptan is effective and well-tolerated for acute migraine attacks; 2.5 mg dose is significantly more effective vs. 1 mg dose. Rizatriptan 10 mg and sumatriptan 100 mg are superior to naratriptan for headache relief. Zolmitriptan 2.5 mg is comparable in efficacy to naratriptan 2.5 mg (note: this was based on one trial, which was stopped early due to supply problems). Naratriptan is associated with lower incidence of AEs vs. rizatriptan, sumatriptan, and zolmitriptan; overall rate of AEs for naratriptan is similar to placebo.</td>
</tr>
<tr>
<td>Frovatriptan oral (2005)87</td>
<td>5 RCTs n=2866</td>
<td>Types of participants: moderate or severe migraine attacks</td>
<td>To evaluate efficacy and tolerability of frovatriptan in acute migraine</td>
<td>Frovatriptan 2.5 mg more effective vs. placebo for pain-free (RR 3.70; 95% CI: 2.59-5.29; p=0.0001 at 2 h, and 2.67; 95% CI: 2.21-3.22; p=0.0001 at 4 h). Frovatriptan also superior to placebo in reducing headache severity: pooled RR 1.66 at 2 h (95% CI: 1.48-1.88; p=0.0001), and 1.38 at 4 h (95% CI: 1.39-1.55; p&lt;0.0001). Risk of headache recurrence reduced by 26% with frovatriptan vs. placebo (RR 0.74; 95% CI: 0.59-0.93; p=0.009). Frovatriptan also superior vs. placebo in improving symptoms associated with migraine (nausea, photophobia, phonophobia). Frovatriptan caused more AEs vs. placebo (RR 1.31; 95% CI: 1.07-1.62; p=0.01).</td>
<td>Frovatriptan is more effective but may cause more AEs than placebo in acute moderate to severe migraine.</td>
<td>Frovatriptan is more effective but may cause more AEs than placebo in acute moderate to severe migraine.</td>
</tr>
<tr>
<td>Almotriptan oral (2007)88</td>
<td>8 RCTs n=4995</td>
<td>Types of participants: adults; IHS criteria for migraine diagnosis</td>
<td>To evaluate comparative efficacy and safety of almotriptan in acute migraine attacks</td>
<td>Almotriptan 12.5 mg significantly more effective vs. placebo for all efficacy outcomes (RRs ranged from 1.47 to 2.15; ARDs ranged from 0.03 to 0.28); no significant differences in any safety outcomes. No significant differences in efficacy outcomes comparing almotriptan 12.5 mg vs. sumatriptan 100 mg &amp; vs. zolmitriptan 2.5 mg. Almotriptan 12.5 mg associated with significantly fewer AEs vs. sumatriptan 100 mg (RR: 0.39; 95% CI: 0.23, 0.67); however, no significant differences between almotriptan and sumatriptan for clinically important AEs (e.g., dizziness, somnolence, asthma, chest tightness).</td>
<td>Almotriptan 12.5 mg is an effective treatment for acute migraine attacks; found to be as effective as sumatriptan 100 mg &amp; zolmitriptan 2.5 mg for 2-h headache relief and pain-free response. Risk of AEs for almotriptan 12.5 mg was similar to placebo &amp; significantly lower than sumatriptan 100 mg.</td>
<td></td>
</tr>
</tbody>
</table>

*Headache relief defined as decrease from initial moderate or severe headache to mild or none; pain-free response defined as reduction in headache severity to mild, moderate, or severe to no pain; sustained pain-free response defined as pain-free at 2 h post-dose, no pain from 2 to 24 h as well as use of no rescue medication or a second dose of study drug.**Headache relief defined as decrease from initial moderate or severe headache to none or mild at 2 and 4 h post-dose; pain-free defined as headache reduced from moderate or severe to none at 2 and 4 h post-dose; sustained relief over 24 h defined as headache relief at 4 h post-dose, maintained for 24 h after treatment (i.e., pain did not return to moderate or severe), with no use of rescue medication or a second dose of study medication. RCTs = randomized; controlled trials; IHS = International Headache Society; CI = confidence interval; AEs = adverse events; ODY = orally disintegrating tablet; RR (risk ratio) for efficacy = proportion of patients achieving outcome in treatment group relative to control group; CI = confidence interval; RR for AEs = relative risk; RRs = pooled rate ratios; ARDs = absolute rate differences; NNT = number-needed-to-treat; NNH = number-needed-to-harm; NS = not significant

within one hour, while pain was mild. Sumatriptan/naproxen was superior (p=0.001) to placebo for 2- through 24-h sustained pain-free response (primary endpoint) (study 1: 26% vs. 8%; study 2: 31% vs. 8%), and for pain-free response at 2 h (study 1: 40% vs. 17%; study 2: 44% vs. 14%). Sumatriptan/naproxen was generally well tolerated.

**Triptan non-responders (switching triptans)**

Oral triptan therapy does not provide headache relief in approximately one-third of patients.14 Since response to a single triptan is not predictable in an individual patient, it may be useful to test a range of different triptans in an individual, in order to select the “ideal triptan” in terms of effectiveness and tolerability.
for that patient. Evidence from clinical trials indicates that patients with a poor response to one triptan can benefit from subsequent treatment with a different triptan.\textsuperscript{22-26} When switching to another triptan, it is generally recommended (according to Product Monographs) to wait 24 hours before using a different triptan.

A multiple attack study evaluated the efficacy and tolerability of five triptans commercially available in Italy (zolmitriptan 2.5 mg, rizatriptan 10 mg, sumatriptan 100 mg, almotriptan 12.5 mg, and eletriptan 40 mg); 30 patients completed the study.\textsuperscript{22} For a total of 30 attacks, patients used a different triptan or placebo for every five consecutive attacks. Different sequences of the five triptans and of the placebo were used. The primary endpoints evaluated were: headache response at 2 h, pain-free at 2 h, and sustained pain-free (at 24 h); intra-patient consistency (percentage of patients obtaining relief in one or three or five of five consecutively treated attacks), and tolerability. No substantial difference in terms of efficacy of the triptans was noted, and all were well tolerated. Although results of this study are of clinical interest, with the small number of subjects (n=30), this study would have limited power to detect differences among triptans.

A study evaluated the efficacy and tolerability of almotriptan 12.5 mg in migraine patients who responded poorly to oral sumatriptan 50 mg (at least two unsatisfactory responses). Patients treated their first attack with open-label sumatriptan 50 mg. Of the 198 sumatriptan non-responders who treated their second attack (99 almotriptan, 99 placebo), 2-h pain relief rates were significantly higher with almotriptan compared to placebo (47.5 vs. 23.2%, \(p<0.001\)); a significant difference was also seen in pain-free rates at 2 h (33.3 vs. 14.1%, \(p<0.005\)). The authors concluded that almotriptan 12.5 mg is an effective and well tolerated alternative for patients who respond poorly to sumatriptan 50 mg.\textsuperscript{24}

In a double-blind, placebo-controlled, parallel group, multicentre study, the tolerability and efficacy of eletriptan was studied in patients (n=446) who had discontinued oral sumatriptan due to lack of efficacy or intolerable adverse events. Patients were randomized to eletriptan 40 mg (E40) or 80 mg (E80), or placebo for treatment of up to three migraine attacks. Two-hour response rates (first-dose, first-attack data) were 59% for eletriptan 40 mg, 70% for eletriptan 80 mg, and 30% for placebo (\(p<0.0001\) for both doses of eletriptan vs. placebo; \(p<0.05\) for E80 vs. E40). Onset of action was rapid, with 1-h headache response rates significantly superior for E40 and E80 compared to placebo. Both E40 and E80 demonstrated significant consistency of response compared to placebo in at least two of three attacks. Adverse events were mild to moderate in severity and dose-related. The authors concluded that eletriptan (40 mg or 80 mg) produced an effective response in patients who had previously discontinued treatment with sumatriptan.\textsuperscript{25}

In a randomized, double-blind, placebo-controlled study of naratriptan in 347 migraine sufferers non-responsive to sumatriptan (self-described), patients’ poor response was confirmed by a single-blind assessment with sumatriptan 50 mg for the treatment of one moderate to severe migraine attack. Patients confirmed as non-responsive (no pain relief at 4 h; non-response confirmed in 63.4% of patients) were randomized to naratriptan 2.5 mg or placebo for treatment of the next migraine attack. Naratriptan was found to be statistically superior to placebo for relief of headache pain at 4 h (41% vs. 19%; \(p<0.001\)), and superior to placebo for pain-free at 4 h (22% vs. 10%; \(p=0.005\)).

Although the above trials indicate that for patients responding poorly to a given triptan, another triptan is able to show efficacy superior to placebo, none of the trials included the original triptan in blinded fashion for comparison in the placebo-controlled portion of the trial. It is therefore impossible to determine from this data whether, had the original triptan been included in the trial, the second triptan would have been superior to it. Nevertheless, the data available does suggest, as does clinical experience, that many patients benefit from switching triptans if the response to the first triptan is not optimal.

**Early intervention**

There is considerable evidence from prospective, randomized, controlled trials of triptans that early intervention when pain is still mild results in higher pain-free and sustained pain-free rates, and more rapid return to normal functioning. Placebo-controlled early intervention trials have been done with zolmitriptan (2.5 mg), frovatriptan (2.5 mg), sumatriptan (50 and 100 mg), eletriptan (20 and 40 mg), sumatriptan fast disintegrating tablets (50 and 100 mg), and rizatriptan (10 mg) (see Table 6).\textsuperscript{25,26} These early intervention trials generally produced higher 2-h pain-free rates than clinical trials in which the headache was not treated until it had become of moderate or severe intensity. In the early treatment studies, methodologies differed from trial to trial, so that they cannot all be directly compared. However, very high 2-h pain-free rates were reported for many trials, including: 57% for zolmitriptan 2.5 mg when patients were treated within 15 minutes of headache onset, 57% for sumatriptan 100 mg, 47% for eletriptan 40 mg, 59% for rizatriptan 10 mg, and 66% for the sumatriptan 100 mg fast disintegrating tablet. These 2-h pain-free rates cannot be directly compared, not only because of differing trial methodologies, but also because the trials had different placebo pain-free rates. Please consult Table 6 for more details.

It is of interest, that early treatment also appears to result in higher 24-h sustained pain-free rates, which were reported for example at 48% for rizatriptan 10 mg.\textsuperscript{32} Whether or not treatment during the migraine aura phase is advisable is discussed in Section 3.

**Headache recurrence**

Return of headache within 24 hours after initial treatment success (i.e., recurrence) occurs in approximately one-third of triptan-treated attacks.\textsuperscript{34} In case of headache recurrence, a second dose of triptan may be taken after an appropriate time interval (i.e., 2 h for most triptans, except 4 h for frovatriptan and naratriptan; the product monograph limits eletriptan 40 mg to one dose per day in Canada, although in some other countries the 80 mg dose is also available; see Section 3 of guideline).

Clinical data derived from 31 triptan, placebo-controlled efficacy trials used in a previous meta-analysis\textsuperscript{15} concluded that triptans with longer half-lives and greater 5-HT\textsubscript{1B} receptor potency had the lowest rate of headache recurrence. Mean
headache recurrence rates were lowest for frovatriptan (17%), eleetropan (24%), and naratriptan (25%). However, it is problematic to compare recurrence rates among triptans, as a headache can only recur if it responded to the triptan in the first place.

**Recommendations (triptans)**

1. **Strong recommendation, high quality evidence:** Triptans (almotriptan, eleetropan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan) are recommended for the acute treatment of migraine attacks that are likely to become moderate or severe.

2. **Strong recommendation, moderate quality evidence:** If a patient does not respond well to one triptan or tolerates it poorly, other triptans should be tried over time in subsequent attacks. It is recommended that patients wait 24 hours before trying another triptan.

3. **Strong recommendation, high quality evidence:** If migraine response to sumatriptan is inadequate, consider use of naproxen sodium 500 mg to be given simultaneously with the triptan.

4. **Strong recommendation, low quality evidence:** If migraine response to other triptans (other than sumatriptan) is inadequate, consider the addition of an NSAID (e.g., naproxen sodium) to be given simultaneously with the triptan.

5. **Strong recommendation, high quality evidence:** Patients with migraine attacks that are usually moderate or severe in intensity should be advised to take triptans early during their migraine attacks while pain is mild (caution the patient regarding medication overuse headache – see Section 3).

**Ergot Derivatives**

**Overview**

The ergot derivatives are older drugs, and clinical trials are generally of poor quality. There are very few randomized, placebo-controlled trials on efficacy of ergot derivatives in acute migraine treatment. The ergot derivatives, like the triptans, are vasoconstrictors, and are contraindicated in patients with cardiovascular disease. Because they are less specific than the triptans and affect a greater variety of receptors, they generally have more side effects, such as nausea. The ergot derivatives are divided into dihydroergotamine (DHE), which is available in an injectable and an intranasal formulation, and ergotamine, which is available in oral tablet form only (in combination with caffeine).

a) **Dihydroergotamine (DHE)**

**Evidence Summary**

**Intranasal (IN):** The IN formulation of DHE has shown variable to superior efficacy compared with placebo in acute migraine, however, it was less effective than IN or SC sumatriptan. In a multicentre, randomized, double-blind, double-dummy, crossover study (n=368, treating two attacks), significantly more patients obtained headache relief at 60 minutes after treatment with IN sumatriptan 20 mg (as a single dose in one nostril) than with IN DHE 1 mg (given as one 0.5 mg spray in each nostril plus optional 0.5 mg in each nostril, 30 min after first dose) (53% vs. 41%; p<0.001). In a multicentre, randomized, double-blind, double-dummy, crossover study (n=266), SC sumatriptan (6 mg) was significantly better than IN DHE (1 mg plus optional 1 mg) at providing headache relief and resolution of headache at all time points from 15 minutes to 2 hours (p<0.001 at all time points); SC sumatriptan had a faster onset of action than IN DHE. Headache relief was achieved and maintained for 24 hours in 54% of sumatriptan-treated patients compared with 39% of DHE IN-treated patients (p<0.001). However, more patients reported headache recurrence after treatment with SC sumatriptan (31%) than after IN DHE (17%).

**Subcutaneous:** In a multicentre, randomized, double-blind clinical trial (n=295), headache relief with SC DHE (1 mg) was similar to that of SC sumatriptan 6 mg (85.5% vs. 83.3% by 4 hours, respectively); DHE had a slower onset of action but fewer headache recurrences compared with sumatriptan (17.7% vs. 45%, respectively; p<0.001).

**Recommendation (dihydroergotamine)**

1. **Weak recommendation, moderate quality evidence:** Dihydroergotamine (intranasal or subcutaneous self-injection) may be considered for the acute treatment of moderate or severe migraine attacks.

b) **Ergotamine**

**Overview**

Ergotamine use is problematic in migraine because of poor oral absorption, vasoconstrictive side effects, and the frequent occurrence of dose limiting side effects such as nausea, which make it difficult to achieve a therapeutic dose in many patients. However, the cost of ergotamine is much lower than that of triptans, and it may be an option in selected patients who do not respond to triptans or are unable to pay for triptans.

**Evidence Summary (comparative studies with triptans)**

In a multicentre, randomized, double-blind, double-dummy, parallel-group trial (n=580), oral ergotamine (2 mg plus caffeine 200 mg) was inferior to oral sumatriptan (100 mg dispersible tablet) for 2 h headache relief (48% vs. 66%, respectively; p<0.001) and 2 h pain-free (13% vs. 35%, respectively; p<0.001). However, 41% of patients in the sumatriptan group had headache recurrence within 48 hours compared with 30% in the ergotamine/caffeine group (p=0.009). In another multicentre, randomized, placebo-controlled, double-blind trial, parallel-group study (n=733), oral ergotamine (2 mg plus caffeine 200 mg) was inferior to oral eleetropan 40 mg and 80 mg for 2-h headache response (33% vs. 54% for eleetropan 40 mg; p<0.001) and 2-h pain-free (10% vs. 28% for eleetropan 40 mg vs. 5% for placebo; p<0.001). In a third trial, almotriptan was more effective than caffeine/ergotamine, with significantly more patients becoming pain-free at 2 h post-dose (21% vs. 14%, respectively; p<0.05); 2-h pain-relief rate was 58% vs. 45%, respectively (p<0.01).

A meta-analysis of oral sumatriptan concluded that ergotamine (plus caffeine) was significantly less effective than oral sumatriptan.
Recommendations (ergotamine)

1. Strong recommendation, moderate quality evidence:
   Ergotamine should not be used routinely for acute migraine attacks, due to inferior efficacy compared to the triptans, and the potential for more side effects.

2. Weak recommendation, moderate quality evidence:
   Ergotamine may be considered for use in some patients, for example when triptans are not available to the patient or not effective.

2. NON-SPECIFIC AGENTS

Simple Analgesics and NSAIDs

Overview

Over-the-counter (OTC) analgesics are used exclusively for migraine attacks by about 60% of patients. However, most trials of OTC medications have systematically excluded patients with severe disability (e.g., requiring bed rest) during 50% or more of attacks, or vomiting with more than 20% of attacks. When data from 11 adequately designed trials were combined in a systematic review (in 2003), OTC analgesics (e.g., acetaminophen alone or in combination with caffeine), ASA (alone or in combination with either caffeine and/or acetaminophen), ibuprofen] were more effective than placebo for headache relief within 2 h, and a significant minority of patients achieved pain-free status within 2 h. Up to 76% of patients returned to normal functioning, particularly if their symptoms and disability were mild to moderate. The authors concluded that OTC medications are only indicated in patients with mild to moderate migraine symptoms, and patients who experience disability during most attacks and/or vomiting in more than 20% of attacks are poor candidates for OTC-exclusive therapy.

Various NSAIDs including ibuprofen, naproxen sodium, diclofenac potassium, and others have been studied in acute migraine. There appear to be no significant differences in efficacy among the various NSAIDs; however, there is a lack of head-to-head comparisons. NSAIDs appear to be effective for mild to moderate attacks (and perhaps in severe attacks in some patients); however, they are associated with a risk for gastrointestinal adverse effects, including bleeding. NSAIDs should be avoided in patients with peptic ulceration, history of gastrointestinal bleed, or ASA-induced asthma. Trials with rofecoxib, a COX-2 inhibitor, have also demonstrated efficacy in migraine; however, rofecoxib is no longer available on the market, due to a risk of cardiovascular adverse effects.

a) Acetylsalicylic Acid (ASA)

Evidence Summary

ASA with or without Metoclopramide (see Table 7)

A Cochrane systematic review (2010) of 13 trials comparing ASA (900 or 1,000 mg) alone (pain-free at 2 h: 24% vs. 11% for placebo; NNT=8.1) or in combination with metoclopramide (10 mg) (pain-free at 2 h: 18% vs. 7% for placebo; NNT=8.8), with placebo or other active comparators (mainly sumatriptan 50 or 100 mg) concluded that ASA 1,000 mg is an effective treatment for acute migraine in adults, with efficacy similar to that of sumatriptan 50 mg or 100 mg; the addition of metoclopramide 10 mg improved relief of nausea and vomiting. Sumatriptan 100 mg was superior to ASA (900 mg) plusmetoclopramide (10 mg) for pain-free at 2 h (28% vs. 18%, respectively; relative benefit of ASA + metoclopramide vs. sumatriptan was 0.63, giving an NNT of 9.8). Adverse effects were mainly mild and transient, were slightly more common with ASA than placebo, but less common than with sumatriptan 100 mg. However, further head-to-head studies are needed to establish the efficacy of ASA compared to other triptans and NSAIDs.

Effervescent ASA (see Table 7)

An individual patient data meta-analysis (2007) of three randomized, controlled trials of effervescent ASA (eASA) concluded that eASA 1,000 mg is as effective as sumatriptan 50 mg (pain-free at 2 h: 27.1% vs. 29%, respectively, vs. 15.1% for placebo) for the treatment of acute migraine attacks (including severe attacks), and has a better side effect profile.

Recommendation (ASA)

1. Strong recommendation, high quality evidence: ASA (975-1,000 mg tablets or effervescent formulation), given with oral metoclopramide (10 mg) if nausea is present, is recommended for the acute treatment of migraine attacks of all severities.

b) Ibuprofen

Evidence Summary (see Table 7)

A systematic review/meta-analysis (2007) of five trials of low-dose ibuprofen concluded that ibuprofen (200 and 400 mg) is effective in reducing headache intensity and rendering adult patients pain-free at 2 h compared to placebo (NNT for pain-free at 2 h=13 for 200 mg, and =9 for 400 mg); photophobia and phonophobia improved with the 400 mg dose only. Adverse effects were similar for ibuprofen and placebo.

A Cochrane systematic review (2010) determined the efficacy and tolerability of ibuprofen alone or in combination with an antiemetic, compared to placebo and other active interventions in the treatment of acute migraine headaches in adults. Nine studies (4273 participants, 5223 attacks) fulfilled entry criteria, and were included in the analysis; none of the studies combined ibuprofen with a self-administered antiemetic. All studies utilized single doses of medication. For ibuprofen 400 mg versus placebo, NNTs for 2-h pain-free (26% vs. 12%, respectively, 2-h headache relief (57% vs. 25% respectively), and 24-h sustained headache relief (45% vs. 19%, respectively) were 7.2, 3.2 and 4.0, respectively. For ibuprofen 200 mg versus placebo, NNTs for 2-h pain-free (20% vs. 10%, respectively) and 2-h headache relief (52% vs. 37%, respectively) were 9.7 and 6.3, respectively. The 400 mg dose was significantly better for 2-h headache relief than 200 mg. Solubilized formulations of ibuprofen 400 mg (e.g., liquid containing capsules) were significantly superior to standard tablets for 1-h (but not 2-h) headache relief (NNT=3.9 for solubilized formulations vs. NNT=8.3 for regular tablets for 1-h headache response; p=0.0114). However, there are no studies directly comparing solubilized formulations with standard formulations. The Cochrane review concluded that ibuprofen is an effective treatment for acute migraine headache, providing pain relief in about half of sufferers; however, it only provided
complete relief from pain (approximately 1 in 4 patients taking ibuprofen 400 mg) and associated symptoms in a minority of sufferers. For all efficacy outcomes, NNTs were better with 400 mg than 200 mg (compared to placebo) but the 400 mg dose achieved statistical significance only for headache relief at 2 h. Soluble formulations provided more rapid relief. Adverse effects with ibuprofen were generally mild and transient.

In a randomized, placebo-controlled trial comparing ibuprofen (400 mg) with rizatriptan (10 mg), rizatriptan was superior in 2-h headache relief (73% vs. 53.8%; p=0.0001) and in use of rescue medication, but not for 2-h pain-free and 24-h headache relapse.54

**Recommendation (ibuprofen)**

1. **Strong recommendation, high quality evidence:** Ibuprofen [400 mg tablet or solubilized (liquid containing capsules) formulation] is recommended for the acute treatment of migraine attacks of all severities.

2. **Strong recommendation, moderate quality evidence:** Ibuprofen (400 mg) in solubilized formulation (liquid containing capsules) is recommended for the acute treatment of migraine attacks of all severities for patients desiring a faster onset of therapeutic effect as compared to the regular ibuprofen tablets.

c) Naproxen Sodium

**Evidence Summary** (see Table 7)

A systematic review/meta-analysis (2010) of four trials (one paper reported results of two trials, and was treated as two separate trials) of naproxen sodium concluded that it was more effective than placebo in reducing pain intensity and providing pain-free within 2 h in adults with moderate or severe migraine attacks [pooled risk ratio for headache relief at 2 h = 1.58 (p<0.00001), and pain-free at 2 h = 2.22 (p=0.0002)].55 Three of the studies used 500 mg doses of naproxen sodium, and one study used 825 mg. Pain-free at 2 h was relatively better with naproxen sodium 825 mg than 500 mg (RR 4.26, 95% CI 1.96-9.27 vs. RR 1.83, 95% CI 1.42-2.36), as well as sustained pain-free response (RR 4.44, 95% CI 1.91-10.32 vs. RR 1.55, 95% CI 1.15-2.09). In Europe, 825 mg is the highest recommended dose for acute migraine, whereas lower doses are generally recommended in North America (i.e., 275-550 mg). There was no significant difference in headache recurrence rate between naproxen sodium and placebo. Naproxen sodium generally relieved nausea, photophobia, and phonophobia significantly better than placebo. Adverse events commonly associated with naproxen sodium were nausea, dizziness, dyspepsia, and abdominal pain. The efficacy of naproxen sodium relative to other acute therapies requires head-to-head clinical trials. Naproxen sodium is preferred over naproxen (base) for acute migraine due to its faster onset of action. However, controlled release formulations of naproxen sodium would not be appropriate for acute migraine treatment.

**Recommendation (naproxen sodium)**

1. **Strong recommendation, high quality evidence:** Naproxen sodium in immediate release formulation (500 or 550 mg; up to 825 mg, if needed and tolerated) is recommended for the acute treatment of migraine attacks of all severities.

d) Diclofenac Potassium

**Overview**

Diclofenac sodium is available in Canada only as an enteric-coated or extended-release tablet with a prolonged release of active drug, and is indicated for chronic pain. Because of a slow onset of action, these preparations would not be suitable for the acute treatment of migraine attacks in most patients.56 Diclofenac potassium is available as an immediate-release tablet, providing a rapid onset of action for the treatment of acute pain conditions. Diclofenac potassium for oral solution, a novel, water-soluble buffered powder formulation, has been available in other countries, and has been recently been approved for use in Canada specifically for the acute treatment of migraine attacks in adults. It has a time to maximum plasma concentration (Tmax) of approximately 15 minutes, suggesting the potential for a rapid onset of effect.57,58

**Evidence Summary**

A Cochrane systematic review (2012) included five studies in adults (n=1356) comparing oral diclofenac potassium with placebo, and also with sumatriptan in one study (none of the studies combined diclofenac with an antiemetic).59 The review concluded that based on limited data, oral diclofenac potassium 50 mg is an effective treatment for acute migraine, reducing moderate to severe pain to no more than mild pain (headache relief in about 55% (NNT=6.2) of those treated, to no pain (pain-free) at 2 h in approximately 22% (NNT=8.9), and to no pain sustained to 24 h (pain-free at 24 h) in approximately 19% (NNT=9.5). There were insufficient data to evaluate other doses of oral diclofenac (e.g., 100 mg), or to compare different formulations or different dosing regimens. Adverse effects of diclofenac potassium were mostly mild to moderate intensity and self-limiting, and were not significantly different from placebo over the short term. Only one study compared oral diclofenac with an active comparator (oral sumatriptan 100 mg).60 This study used a primary efficacy criterion of migraine headache pain recorded on a 100 mm visual analog scale (VAS) 2 h after dosing. Diclofenac potassium was more effective than placebo in reducing headache pain at 2 h (p<0.001; 50 mg and 100 mg doses had similar efficacy); no statistically significant difference was found between either dose of diclofenac potassium and sumatriptan 100 mg. Both doses of diclofenac potassium were significantly better than placebo and sumatriptan in reducing nausea at 2 h. Further head-to-head trials are needed to establish the place in therapy for diclofenac potassium relative to alternative acute treatments for migraine.

A multicentre (Europe), randomized, controlled, double-blind, double-dummy, cross-over trial compared single doses of diclofenac potassium 50 mg sachets (powdered formulation for oral solution) and 50 mg tablets with placebo in 328 patients with migraine pain (888 attacks).61 For the primary endpoint (pain-free at 2 h), 24.7% of patients were pain-free at 2 h post-dose with diclofenac sachets, 18.5% with diclofenac tablets, and 11.7% with placebo. Treatment differences were significant for sachets vs. placebo (p<0.0001), tablets vs. placebo (p=0.004),
Table 4: Triptans - Randomized, double-blind, comparative trials versus other triptans* [part 1]**

<table>
<thead>
<tr>
<th>Drugs, doses, dosage form</th>
<th>Study design, pts included in analysis (n), primary endpoints</th>
<th>Results (primary endpoints)</th>
<th>Conclusions/comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zolmitriptan 2.5/5 mg vs. sumatriptan 5/50 mg; oral tablets</td>
<td>PG, MC; up to 6 attacks treated over 6 months; n=1212 (treated at least 2 attacks)</td>
<td>2-h headache response: Z-2.5 mg: 67%; Z-5 mg: 64.8%; S-25 mg: 59.6%; S-50 mg: 63.8%</td>
<td>Z-2.5/5 mg at least as effective as S-25/50 mg for all parameters studied; Z- 2.5 mg significantly more effective vs. S-50 mg for 2 h &amp; 4 h headache response; Z-2.5/5 mg significantly more likely to have pain relief over 24 h vs. S (Note: Z-5 mg is not available in Canada)</td>
</tr>
<tr>
<td>Zolmitriptan 2.5/5 mg vs. sumatriptan 50 mg; oral tablets</td>
<td>PG, DD, MC; 1:1:1 ratio; up to 6 attacks treated; n=1522 (treated at least 2 attacks)</td>
<td>2-h headache response:</td>
<td>Similar efficacy for Z-2.5/5 mg vs. S-50 mg; similar rates of meaningful migraine relief (1, 2, or 4 h) &amp; sustained (24 h) pain relief (Note: Z-5mg is not available in Canada)</td>
</tr>
<tr>
<td>Rizatriptan 10 mg vs. naratriptan 2.5 mg; oral tablets</td>
<td>PC, MC, single attack; n=522</td>
<td>Time to headache relief within 2 h</td>
<td>R more effective than N &amp; provided earlier headache relief than N; more patients pain-free at 2 h with R vs. N (44.8% vs. 20.7%, p&lt;0.001); earlier relief of associated symptoms &amp; return to normal function in 2 h with R vs. N (p&lt;0.001); similar overall pain relief over 24 h for R &amp; N</td>
</tr>
<tr>
<td>Rizatriptan 10/20/40 mg vs. sumatriptan 100 mg; oral tablets</td>
<td>PC, PG, MC, dose-ranging study; n=449</td>
<td>2-h headache response</td>
<td>Efficacy of R-10/20 mg comparable to S-100 mg; R-40 mg superior to S-100 mg but high frequency of ADRs with R-40 mg (Note: R-20/40 mg not available in Canada)</td>
</tr>
<tr>
<td>Rizatriptan 5/10 mg vs. sumatriptan 25/50 mg; oral tablets</td>
<td>PC, CO, MC; 2 attack trial, 5 sequence groups; active vs. placebo ratio 2:1; n=1329 (treated at least one attack)</td>
<td>Time to pain relief within 2 h: R superior to S; R-10 mg vs. S-50 mg: hazard ratio 1.14 (p=0.05)</td>
<td>R-5/10 mg provided faster relief of headache pain &amp; greater relief of migraine symptoms (esp. nausea) than S-25/50 mg; response to R better on other measures (e.g., functional disability, satisfaction)</td>
</tr>
<tr>
<td>Rizatriptan 5/10 mg vs. sumatriptan 25/50 mg; oral tablets</td>
<td>PC, PG, TD, MC; single-dose study; n=1091</td>
<td>Time to pain relief within 2 h**</td>
<td>Faster onset of pain relief (at 1 h) with R-10 mg vs. S-50 mg (but no difference at 2 h); secondary endpoints favoured R over S</td>
</tr>
<tr>
<td>Rizatriptan 5/10 mg vs. sumatriptan 25/50 mg; oral tablets</td>
<td>PC, 2-attack, CO, 6 treatment sequences; n=1447 (treated at least one attack)</td>
<td>Time to pain relief within 2 h**</td>
<td>Study compared optimum doses of both drugs; similar efficacy; less chest pain with A vs. S</td>
</tr>
<tr>
<td>Almotriptan 12.5 mg vs. sumatriptan 50 mg; oral tablets (encapsulated)</td>
<td>PC, PG, MC, single-dose; n=1173</td>
<td>2-h headache relief**</td>
<td>Greater efficacy for E vs. S (primary and secondary endpoints); E: rapid headache response (1 h) &amp; better sustained response (24 h) vs. S</td>
</tr>
<tr>
<td>Almotriptan 40 mg vs. sumatriptan 100 mg; oral tablets (encapsulated)</td>
<td>PC, DD, MC, single attack, 1:2:1 ratio; n=2072</td>
<td>2-h headache relief: E: 67%; S: 59% (p=0.01)</td>
<td>E-80 mg significantly better than S-50 mg (but similar to S-100 mg for pain-free response (p=0.032), reduction in functional disability (p=0.015) &amp; relief of nausea (p=0.010) at 2 h; significantly fewer AEs with R-10 mg vs. S-100 mg (33% vs. 41%, p=0.014)</td>
</tr>
<tr>
<td>Almotriptan 40/80 mg vs. sumatriptan 50/100 mg; oral tablets (encapsulated)</td>
<td>PC, DD, PG, MC, multiple attack; n=774</td>
<td>1-h headache response** (first attack)</td>
<td>E-80 mg significantly better than S-50 mg (but similar to S-100 mg) for 1 h headache response; E-80 mg significantly superior consistency of response across multiple attacks vs. S-50/100 mg (Note: E-80 mg is not an approved dose in Canada)</td>
</tr>
<tr>
<td>Almotriptan 12.5 mg vs. sumatriptan 25 mg; oral tablets (encapsulated)**</td>
<td>DB, PG, MC, (not PC), single attack; n=1103</td>
<td>Composite endpoint: sustained pain-free = no adverse events (SNAE)</td>
<td>A &amp; Z associated with similar efficacy &amp; overall tolerability; A associated with significantly lower rate of triptan-associated AEs</td>
</tr>
<tr>
<td>Almotriptan 80 mg (40 mg) &amp; zolmitriptan 2.5 mg**; oral tablets</td>
<td>DB, DD, PC, PG, MC, single attack; n=1312</td>
<td>2-h headache response</td>
<td>E-80 mg significantly better than Z-2.5 mg; E-40 mg similar efficacy to Z-2.5 mg (secondary endpoint) AEs more frequent with E-80 mg (Note: E-80 mg is not an approved dose in Canada)</td>
</tr>
</tbody>
</table>

and for sachets vs. tablets (p=0.0035). The NNTs compared with placebo to achieve pain-free at 2 h were 7.75 (95% CI 5.46, 13.35) for sachets, and 15.83 (95% CI 8.63, 96.20) for tablets. Sachets were also superior to tablets for sustained headache resolution, sustained pain-free, and reduction in headache intensity within the first 2 h post-dose (measured on visual analog scale) (p < 0.05). The onset of analgesic effect was 15 minutes for sachet versus 60 minutes for tablets.

In the IMPACT study, the efficacy of diclofenac potassium 50 mg for oral solution (dissolved in approximately two ounces of water) was assessed in a multicentre (U.S.), randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-attack trial in adult sufferers with migraine (moderate or severe attacks). Subjects with vomiting in 20% of migraine attacks or who required bed rest during attacks were excluded. There were four co-primary endpoints. Compared to placebo (n=347), significantly more subjects treated with diclofenac potassium for oral solution (n=343) achieved a 2-h pain-free response (25% vs. 10% for placebo; p<0.001), no nausea (65% vs. 53%; p=0.002), no photophobia (41% vs. 27%; p=0.003). The NNTs compared with placebo to achieve pain-free at 2 h were 7.75 (95% CI 5.46, 13.35) for sachets, and 15.83 (95% CI 8.63, 96.20) for tablets. Sachets were also superior to tablets for sustained headache resolution, sustained pain-free, and reduction in headache intensity within the first 2 h post-dose (measured on visual analog scale) (p < 0.05). The onset of analgesic effect was 15 minutes for sachet versus 60 minutes for tablets.
Table 4: Triptans - Randomized, double-blind, comparative trials versus other triptans* [part 2] continued

<table>
<thead>
<tr>
<th>Triptan</th>
<th>DB, MC, CO; 1-3 attacks; each treatment period not &gt; 3 months</th>
<th>Primary (preference to one treatment via questionnaire with score 0-5): NS difference (2.9 for F vs. 3.0 for Z)</th>
<th>Recurrence rate at 48 h: 18% vs. 22% (NS) AEs: less for F (p&lt;0.05)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diclofenac potassium</td>
<td>n=135 (ITT) 2-h pain-free (PF) 2-h pain relief (PR)** 48-h SPF***</td>
<td>Secondary (preference to one treatment via questionnaire with score 0-5): NS difference (2.9 for F vs. 3.0 for Z)</td>
<td>SPF at 48h: 18% vs. 22% (NS) AEs: less for F (p&lt;0.05)</td>
</tr>
<tr>
<td>Frovatriptan 2.5 mg</td>
<td>n=204 (ITT) 2-h pain-free (PF) 2-h pain relief (PR)** 48-h SPF***</td>
<td>Secondary (preference to one treatment via questionnaire with score 0-5): NS difference (2.9 for F vs. 3.0 for Z)</td>
<td>SPF at 48h: 18% vs. 22% (NS) AEs: less for F (p&lt;0.05)</td>
</tr>
<tr>
<td>Rizatriptan 10 mg</td>
<td>n=200 (ITT) 2-h pain-free (PF) 2-h pain relief (PR)** 48-h SPF***</td>
<td>Secondary (preference to one treatment via questionnaire with score 0-5): NS difference (2.9 for F vs. 3.0 for Z)</td>
<td>SPF at 48h: 18% vs. 22% (NS) AEs: less for F (p&lt;0.05)</td>
</tr>
<tr>
<td>Almotriptan 12.5 mg</td>
<td>n=200 (ITT) 2-h pain-free (PF) 2-h pain relief (PR)** 48-h SPF***</td>
<td>Secondary (preference to one treatment via questionnaire with score 0-5): NS difference (2.9 for F vs. 3.0 for Z)</td>
<td>SPF at 48h: 18% vs. 22% (NS) AEs: less for F (p&lt;0.05)</td>
</tr>
</tbody>
</table>

*p<0.001, and no phonophobia (44% vs. 27%; p<0.001). Pain intensity differences between treatments were significantly lower in the diclofenac potassium group, starting at 30 minutes post-treatment (p=0.013), with significant differences at all time points, thereafter (p<0.001). The most common treatment related adverse event was nausea (4.6% for diclofenac potassium vs. 4.3% for placebo).

Recommendations (diclofenac potassium)

1. Strong recommendation, high quality evidence: Diclofenac potassium (50 mg tablet or powder for oral solution) is recommended for the acute treatment of migraine attacks of all severities.

2. Strong recommendation, moderate quality evidence: Diclofenac potassium powder for oral solution (50 mg) is recommended for the acute treatment of migraine attacks of all severities for patients desiring a faster onset of therapeutic effect as compared to the diclofenac oral tablet formulation.

e) Acetaminophen

Evidence Summary

In a multicenter, randomized, placebo-controlled trial of acetaminophen in adults with migraine, 1,000 mg doses produced pain relief in 57.8% of moderate attacks within 2 h (vs. 38.7% for placebo; p=0.002); 22.4% of patients were pain-free at 2 h (vs. 11.3% for placebo; p=0.01). This trial excluded patients with disabling headaches (requiring bed rest or precluding daily activities more than 50% of the time), or those with vomiting in more than 20% of attacks.52 In another, multicenter, randomized, placebo-controlled trial (n=346 adults with migraine), significantly more patients treated with acetaminophen (1,000 mg) had pain relieved after 2 h (52.0%) compared to those treated with placebo (32.0%; p=0.001). However, acetaminophen was not significantly better than placebo for pain-free at 2 h. Patients were excluded if they had a history of severely incapacitating migraines with more than 50% of episodes requiring bed rest (or prohibiting performance of daily activities), or more than 20% of episodes included vomiting.53 A Cochrane systematic review (2010) of acetaminophen for acute migraine headaches in adults (n=2769; 4062 attacks; see Table 7), which included ten trials (including the two trials discussed above, which contributed almost 99% of the data for primary outcomes), concluded that acetaminophen 1,000 mg alone may be a useful first-line treatment for individuals with migraine headache that do not cause severe disability. Acetaminophen was superior to placebo, with NNTs of 12.0, 5.2 and 5.0 for 2-h pain-free and 1- and 2-h headache relief, respectively.54 When combined with metoclopromide, acetaminophen provided similar efficacy to oral sumatriptan.
Table 5: Triptans – Randomized, double-blind comparative studies versus NSAIDs/analgesic

<table>
<thead>
<tr>
<th>Drugs, doses, # pts included in analysis (n)</th>
<th>Study design, # pts included in analysis (n), primary endpoints</th>
<th>Results</th>
<th>Conclusions/comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sumatriptan (S) 100 mg vs. lysine acetylsalicylate 1620 mg + metoclopramide (LAS + M) 10 mg</td>
<td>PC, PG, MC, 2 attack trial; n=421</td>
<td>2-h headache response** 2-h headache response (1st attack): S: 57%; LAS + M: 53% (NS); 2-h pain-free (secondary) 1st attack: S: 30%; LAS + M: 22% (NS)</td>
<td>Both S &amp; LAS + M superior to P; similar efficacy for S and LAS + M; LAS + M significantly more effective for nausea relief than S &amp; better tolerated. (Note: lysine acetylsalicylate is not available in Canada)</td>
</tr>
<tr>
<td>Sumatriptan (S) 100 mg vs. tolfenamic acid (TA) 200 mg</td>
<td>PC, PG, 2 attack trial; n=141</td>
<td>2-h headache response**; Difference in headache severity at 2 h after 1st dose</td>
<td>Both S &amp; TA superior to P; similar efficacy for TA and S; similar frequency of AEs Note: tolfenamic acid is not available in Canada</td>
</tr>
<tr>
<td>Sumatriptan (S) 100 mg vs. diclofenac-potassium (DP) 50/100 mg</td>
<td>DD, CO, MC, with-in patient trial, 4 attack trial, 4 treatment sequences; n=144</td>
<td>2-h VAS: NS difference between S &amp; DP (both doses similarly effective); DP provided significant pain relief from 60 min after dose (S: from 90 min after dose); DP superior to S in reducing nausea</td>
<td>DP is effective, fast-acting and well tolerated and some advantages over S; no advantage of DP 100 mg vs. DP 50 mg; unable to evaluate headache response or pain-free response from VAS</td>
</tr>
<tr>
<td>Sumatriptan (S) 100 mg vs. ASA 900 mg + metoclopramide (A + M) 10 mg</td>
<td>PG, MC, 3 attack trial; n=358</td>
<td>2-h headache response**</td>
<td>66% of S patients vs. 45% of A + M patients rated therapy as reasonable, good or excellent (p&lt;0.001)</td>
</tr>
<tr>
<td>Sumatriptan (S) 50 mg (encapsulated) vs. effervescent ASA 1000 mg vs. ibuprofen (I) 400 mg</td>
<td>PC, DD, MC, 3-fold CO; n=192</td>
<td>2-h headache response: ASA: 52.5%; I: 60.2%; S: 55.8% (NS)</td>
<td>Effervescent ASA 1000 mg is as effective as S-50 mg and I-400 mg but S more effective for pain-free at 2 h</td>
</tr>
<tr>
<td>Sumatriptan (S) 50 mg vs. AAC (acetaminophen 500 mg, ASA 500 mg, caffeine 130 mg); all encapsulated</td>
<td>PC, MC; 2:2:1 randomization; drugs taken at first sign of migraine attack; n=171</td>
<td>SPID4: significantly greater in AAC group vs. S group</td>
<td>AAC significantly superior to S taken at first sign of attack; encapsulation may affect kinetics; excluded patients with vomiting&gt;20% of attacks or bed rest&gt;50% of attacks (Note: AAC combination is not available in Canada)</td>
</tr>
<tr>
<td>Sumatriptan (S) 50 mg (encapsulated) vs. domperidone (DO) 10 mg + acetaminophen (AC) 500 mg (fixed combination) (n=161)</td>
<td>DD, PC, CO, MC, 2 attack trial; n=171</td>
<td>2-h headache response: S: 33.3%; DO/AC: 36.4% (NS); NS difference for nausea/vomiting reduction by both</td>
<td>Similar efficacy for both; low 2-h response rates for both (reason unknown); (Note: DO/AC fixed combination is not available in Canada)</td>
</tr>
<tr>
<td>Zolmitriptan (Z) 2.5 mg vs. ASA 900 mg + metoclopramide (A + M) 10 mg</td>
<td>MC, PG, 3 attacks; n=666</td>
<td>2-h headache response**</td>
<td>Possible selection bias (mostly good responders to A + M; mostly triptan-naïve); both well-tolerated; higher pt satisfaction with Z vs. A + M (83% vs. 75%, p=0.03)</td>
</tr>
</tbody>
</table>

*Note: some of the trials listed in this table are also included in meta-analyses in Tables 3 and 7. ** 2-h headache response: reduction in pain from severe/moderate to mild/no pain within 2 hours of treatment. P = placebo; PC = placebo-controlled; DD = double-dummy; PG = parallel group; MC = multicentre, CO = cross-over; NS = not statistically significant; AEs = adverse events
Table 6: Triptans - Early intervention: randomized, double-blind, prospective trials²⁷-³³

<table>
<thead>
<tr>
<th>Drug and dose</th>
<th>Study design, # patients included in analysis (n), primary endpoints</th>
<th>Results</th>
<th>Comments/conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zolmitriptan 2.5 mg oral²⁷</td>
<td>RA, DB, PC, PG; n=280 Pain-free at 2 h: attacks treated during mild phase within 4 h of onset (time to treatment was recorded) vs. placebo</td>
<td>Pain-free at 2h (all pts): Z: 43.4%; P: 18.4% (p&lt;0.0001) Pain-free at 2 h (treated within 15 min of onset): Z: 57%; P: 20% (p&lt;0.001)</td>
<td>Most pts treated early (&gt;50% within 30 min of onset); high pain-free rates with treatment while pain is mild &amp; ↓ progression to more severe migraine; lower incidence of adverse effects with early treatment</td>
</tr>
<tr>
<td>Frovatriptan 2.5 mg oral (2 attacks)²⁸</td>
<td>RA, DB, PC, two-way crossover: Dose 1 taken at onset of mild headache pain; Dose 2 could be taken from 2 h after Dose 1, only if headache progresses to moderate or severe (one dose active, other placebo; dosing order reversed for attack 2); n=241 Pain-free at 2 h (Dose 1); use of Dose 2 and/or rescue meds, pain severity, functional impairment, headache recurrence</td>
<td>Pain-free at 2 h: F: 28%; P: 20% (p&lt;0.04); benefit sustained up to 4 h post-dose (p=0.003) Sustained pain-free: 40% with early use of F vs. 31% with later use (p&lt;0.05) Early use of F: sign, ↓ re-medication (p&lt;0.001), prevented headache progression (p&lt;0.001), ↓ pain burden &amp; functional disability (p&lt;0.001)</td>
<td>Early use of F resulted in higher, earlier and sustained pain-free response, prevented progression to moderate/severe headache and ↓ pain burden &amp; functional disability; long half-life of F – suitability for early intervention</td>
</tr>
<tr>
<td>Sumatriptan 50/100 mg oral²⁹</td>
<td>RA, DB, DD, PC, PG (2 identical trials); 1:1:1 ratio S-50 mg, S-100 mg, P; pts treated attacks at first sign of pain, while mild pain (not more than 2 h after onset); n=354 (study 1); n=337 (study 2) Pain-free at 2 h (S-50 mg vs. P) (primary endpoint)</td>
<td>Pain-free at 2 h (pooled results): S-50 mg: 50%; P: 29% (p&lt;0.001) S-100 mg: 57%; P: 29% (p&lt;0.001)</td>
<td>Treatment of migraine at first sign of pain with S-50/100 mg provides superior pain-free relief at 2 &amp; 4 h vs. P; S provided freedom from migraine-associated symptoms in most patients at 2 h</td>
</tr>
<tr>
<td>Eletriptan 20/40 mg oral²⁹</td>
<td>RA, DB, PC, PG (33 centres); n=565 1:1:1 ratio E-20 mg, E-40 mg, P; patients treated attacks as soon as soon as they had typical migraine headache (after aura phase ended) &amp; encouraged (not required) to take study med when pain was mild Pain-free at 2 h</td>
<td>Pain-free at 2 h (all patients; treated at any baseline severity): E-20 mg: 35%; P: 22% (p=0.01) E-40 mg: 47%; P: 22% (p&lt;0.0001) Pain-free at 2 h (treated when pain was mild): E-40 mg: 68%; P: 25% (p=0.0001) (for E-20 mg: NS)</td>
<td>Early treatment with E-40 mg when pain was mild resulted in higher pain-free and sustained pain-free rates; sustained pain-free maintaine over 24 h post-dose with E vs. P</td>
</tr>
<tr>
<td>Sumatriptan oral fast-disintegrating 50/100 mg³⁰</td>
<td>RA, DB, PC, PG (54 centres); n=432 1:1:1 ratio S-50 mg, S-100 mg, P; patients treated attack within 1h of onset of mild pain &amp; only while pain was mild Pain-free at 2 h</td>
<td>Pain-free at 2 h: S-50 mg: 51%; P: 20% (p&lt;0.001) S-100 mg: 66%; P: 20% (p&lt;0.001) Normal function restored in sign. greater % pts (p&lt;0.05) treated with S vs. P from 45 min post-dose for S-100 mg &amp; 1 h post-dose for S-50 mg Median lost time equivalents (during 24 h post-dose; paid work &amp; activities outside paid work) sign. lower in each S group vs. P</td>
<td>S fast disintegrating oral formulation confers rapid, sustained restoration of functional ability</td>
</tr>
<tr>
<td>Sumatriptan 50/100 mg oral³¹</td>
<td>RA, DB, PC, PG (25 centres); n=361 1:1:1 ratio S-50 mg, S-100 mg, P; patients treated attack within 2 h of first sign of migraine pain &amp; only while pain was mild. Pain-free at 2 h</td>
<td>Pain-free at 2 h: S-50 mg: 50%; S-100 mg: 66%; P: 20% (p&lt;0.001) Sustained up to 4 h post-dose (time to recurrence of pain) sign. greater % pts (p&lt;0.05) treated with S vs. P from 45 min post-dose for S-100 mg &amp; 1 h post-dose for S-50 mg Median lost time equivalents (during 24 h post-dose; paid work &amp; activities outside paid work) sign. lower in each S group vs. P</td>
<td>Both doses of S significantly superior to P for 2-h pain-free; higher pain-free rates when S taken while headache was mild vs. older trial (taken when moderate or severe pain)</td>
</tr>
<tr>
<td>Rizatriptan 10 mg oral³²</td>
<td>Two studies (TAME1, TAME2): RA, DB, PC, PG (46 centres); n=1030; 2:1 ratio R 10 mg vs. P; patients treated within 1 h of migraine onset, while pain was mild Pain-free at 2 h &amp; sustained pain-free at 24 h</td>
<td>TAME1: Pain-free at 2 h: R: 57.3%; P: 31.1% (p&lt;0.001) Sustained pain-free at 24 h: R: 49.6%; P: 23.2% (p&lt;0.001) TAME2: Pain-free at 2 h: R: 58.9%; P: 31.1% (p&lt;0.001) Sustained pain-free at 24 h: R: 48.0%; P: 24.6% (p&lt;0.001)</td>
<td>R 10 mg significantly superior to P when treating migraine early, while pain is mild</td>
</tr>
</tbody>
</table>

P = placebo; Z = zolmitriptan; F = frovatriptan; S = sumatriptan; E = eletriptan; RA = randomized; CO = controlled; DB = double-blind; PC = placebo-controlled; PG = parallel group; DD = double dummy; NS = not statistically significant
1 mg nasal spray was compared to a combination of butalbital 50 mg, caffeine 40 mg, ASA 325 mg, and codeine phosphate 30 mg in patients with moderate to severe migraine.\(^6\) Butorphanol nasal spray was more effective than the butalbital-containing combination in treating migraine pain (primary efficacy measure was pain intensity difference during first two hours); butorphanol had a rapid time to onset of 15 minutes; however, it was associated with more side effects than the butalbital-containing product.

c) Oral Tramadol plus Acetaminophen

**Overview**

Tramadol is an analgesic that binds weakly to μ-opioid receptors, and also inhibits serotonin and norepinephrine reuptake. As with opioids, tramadol use is associated with adverse effects such as central nervous system (CNS) depression and respiratory depression, dependence, withdrawal reactions, and the potential for abuse (less potential for abuse than opioids).\(^7\)

**Evidence Summary**

There is one published randomized, multicentre, placebo-controlled trial of oral tramadol and acetaminophen combination (2 tablets: total dose 75 mg/650 mg; n=305) in acute migraine.\(^2\) At 2 h after dosing, the treatment response (i.e., headache relief; primary endpoint) for tramadol/acetaminophen was 55.8% vs. 33.8% for placebo (p<0.001); subjects in the tramadol/acetaminophen group were more likely than those in the placebo group to be pain-free at 2 h (22.1% vs. 9.3%; p≤0.007). Photophobia and phonophobia were significantly less common with tramadol/acetaminophen than placebo at 2 h, but not migraine-related nausea. Treatment-related adverse events included nausea, dizziness, vomiting, and somnolence.

**Recommendations (opioids and tramadol)**

1. **Strong recommendation, low quality evidence:** Oral opioids, including codeine, are not recommended for routine use in migraine, due to lack of evidence for superiority to standard drugs (NSAIDs and triptans), and the risk of dependence/abuse, potential for development of medication overuse headache, and the possibility of a withdrawal syndrome following discontinuation.

2. **Weak recommendation, low quality evidence:** Codeine-containing combination analgesics may be considered for patients with moderate or severe migraine attacks when triptan and/or NSAIDs are ineffective or contraindicated, and for occasional use as rescue medication when the patient’s regular medication has failed. Frequency of use should be closely monitored, preferably with use of headache diaries.

3. **Strong recommendation, low quality evidence:** Tramadol alone or in combination with acetaminophen is not recommended for routine use in migraine, due to lack of evidence for superiority to standard drugs (NSAIDs and triptans), and the risk of dependence/abuse, potential for development of medication overuse headache, and the possibility of a withdrawal syndrome following discontinuation.

---

100 mg for 2 h headache relief (no pain-free data), and relief of photophobia and phonophobia, but with fewer adverse effects than sumatriptan.\(^5\)

**Recommendation (acetaminophen)**

1. **Strong recommendation, high quality evidence:** Acetaminophen (1,000 mg), alone or in combination with oral metoclopramide (10 mg), is recommended for the acute treatment of mild or moderate migraine attacks.

**Opioid- and Tramadol-containing Products**

a) *Oral Opioid-containing Products*

**Overview**

Opioids are associated with significant adverse effects including sedation, dizziness, constipation, tolerance, dependence, and abuse potential. There is also a significant risk of medication overuse headache with frequent use of opioid-containing combination products.\(^1\)

**Evidence Summary**

Oral opioids (e.g., codeine, morphine, hydromorphone, meperidine) and opioid-containing combination products (e.g., ASA/acetaminophen plus codeine) may relieve acute migraine pain in some patients; however, they may aggravate migraine-associated nausea and vomiting. There is a lack of randomized, controlled trials assessing the efficacy of oral opioids and combination products for the symptomatic treatment of migraine. One randomized, double-blind, placebo-controlled trial which compared an acetaminophen-codeine combination to ASA, found no significant difference, although both were superior to placebo in the treatment of acute migraine attacks.\(^6\)

b) *Intranasal Butorphanol*

**Overview**

Butorphanol tartrate is a potent, synthetic mixed agonist-antagonist opioid analgesic for use in the relief of moderate to severe pain. Although butorphanol is not a pure agonist and, theoretically, may have less addiction potential than pure agonists (e.g., hydromorphone, morphine, meperidine), it is associated with similar adverse effects, and the potential for medication overuse headache and abuse/dependence. There have been widespread reports of abuse and dependence, primarily in migraine patients. Butorphanol has effects at the kappa opioid receptor, which can produce unpleasant emotional sensations and dysphoria.\(^7\)

**Evidence Summary**

At the time of marketing, clinical trial experience with butorphanol nasal spray in migraineurs was limited. Subjects with frequent or refractory headache, or those with a prior history of substance abuse, were excluded from butorphanol trials.\(^5\) Butorphanol nasal spray has been shown to be effective in rapidly relieving pain associated with acute migraine (moderate to severe) in two randomized, double-blind, placebo-controlled trials.\(^5,6\) In a randomized, controlled, double-blind, parallel-group trial (n=275 in efficacy analysis), butorphanol 1 mg nasal spray was compared to a combination of butalbital 50 mg, caffeine 40 mg, ASA 325 mg, and codeine phosphate 30 mg in patients with moderate to severe migraine.\(^6\) Butorphanol nasal spray was more effective than the butalbital-containing combination in treating migraine pain (primary efficacy measure was pain intensity difference during first two hours); butorphanol had a rapid time to onset of 15 minutes; however, it was associated with more side effects than the butalbital-containing product.
4. Weak recommendation, moderate quality evidence: Tramadol in combination with acetaminophen may be considered for patients with moderate or severe migraine attacks when triptans and/or NSAIDs are ineffective or contraindicated, and for occasional use as rescue medication when the patient’s regular medication has failed. Frequency of use should be closely monitored, preferably with use of headache diaries.

5. Strong recommendation, low quality evidence: Butalbital-containing analgesics should be avoided (except in exceptional circumstances) for the acute treatment of migraine, due to lack of evidence for superiority to standard drugs (NSAIDs and/or triptans), risk of dependence/abuse, potential for development of medication overuse headache, and the possibility of a withdrawal syndrome following discontinuation of high doses.

Barbiturate (Butalbital)-containing Products

Overview

Butalbital-containing products are associated with significant adverse effects (e.g., sedation, intoxication similar to that produced by alcohol), risk of dependence, abuse potential, risk of medication-overuse headache with frequent use, and a severe withdrawal syndrome (including seizures) on discontinuation of high doses.

Evidence Summary

A qualitative systematic search (1966-2001) concluded that although butalbital-containing products are commonly prescribed for migraine, no evidence in the literature has demonstrated their benefit over other agents or placebo. In a randomized, controlled trial (n=275 in efficacy analysis) comparing butorphanol nasal spray to a combination of butalbital 50 mg, caffeine 40 mg, ASA 325 mg, and codeine phosphate 30 mg, the butalbital-containing combination was inferior to butorphanol in treating migraine pain.

In a recent, randomized, double-blind, placebo-controlled trial (n=442), a butalbital-acetaminophen-coffeine containing combination analgesic was compared to a sumatriptan-naproxen sodium combination. For inclusion, all patients were required to have used butalbital compounds in the past (butalbital responders), and in fact 88% of subjects who entered the study reported current use of butalbital compounds. The study population may have been biased, therefore, in favour of subjects who respond to butalbital-containing analgesics. Despite this, although both the butalbital-containing analgesic and the sumatriptan-naproxen sodium compound were superior to placebo, the sumatriptan-naproxen sodium compound was superior to the butalbital compound on most secondary endpoints, although not for the primary endpoint of sustained pain-free, where there was no significant difference. This study demonstrated that butalbital-containing analgesics may have efficacy in the treatment of acute migraine attacks, but are not superior to an NSAID-triptan combination. Therefore, given the potential problems with butalbital-containing compounds, it would seem difficult to justify their use in acute migraine except for exceptional circumstances.

Recommendation (barbiturates)

1. Strong recommendation, low quality evidence: Barbiturate (i.e., butalbital)-containing combination analgesics should be avoided (except in exceptional circumstances) for the acute treatment of migraine, due to lack of evidence for superiority to standard drugs (NSAIDs and/or triptans), risk of dependence/abuse, potential for development of medication overuse headache, and the possibility of a withdrawal syndrome following discontinuation of high doses.

3. Adjunctive Drugs

Overview

Adjunctive therapies may be used to relieve associated symptoms of migraine (e.g., nausea, vomiting), enhance gastric emptying, or to improve efficacy of acute migraine therapies. Parenteral dopamine antagonists (e.g., metoclopramide, prochlorperazine; administered in the emergency room), used as monotherapy, are effective in relieving migraine-associated nausea, as well as headache (not included in this guideline). In outpatient practice, adjunctive drugs are often used in combination with other effective migraine treatments. There are randomized controlled trials for oral metoclopramide and domperidone as adjunctive drugs in the outpatient setting. Oral or rectal prochlorperazine may be used for relief of migraine-associated nausea and vomiting but there is a lack of RCTs. Although dimenhydrinate is often used by patients for nausea and vomiting associated with migraine, there are no RCTs to support its use, and metoclopramide would appear to be a better choice for most patients based on evidence for efficacy.

Evidence Summary

a) Metoclopramide

Metoclopramide has shown efficacy in combination with other acute therapies. A Cochrane systematic review of ASA with or without metoclopramide (see Acetylsalicylic Acid section and Table 7) concluded that the addition of oral metoclopramide (10 mg) to ASA 1,000 mg improves relief of nausea and vomiting. Limitations of metoclopramide include adverse effects such as sedation, extrapyramidal effects, and the relatively uncommon risk of tardive dyskinesia.

Metoclopramide may improve the efficacy of triptans. In a small, double-blind, randomized, crossover study of 16 adult migraineurs who had failed to receive adequate relief from triptans (i.e., adequate doses of at least two separate trials of the same triptan, or at least two trials involving different triptans) treated one migraine with each treatment: sumatriptan 50 mg plus metoclopramide 10 mg, or sumatriptan 50 mg plus placebo. Patients treated their migraines when they were moderate or severe in intensity. Meaningful relief was attained in 10 (63%) of 16 migraines treated with the combination of sumatriptan plus metoclopramide, compared with 5 (31%) of 16 migraines treated with sumatriptan plus placebo. The combination was well tolerated. Whether initiating therapy when pain was mild or
Table 7: Meta-analyses/systematic reviews of acetaminophen, ASA and NSAIDs for acute migraine treatment

<table>
<thead>
<tr>
<th>Drug (publication date); number of trials included; number of participants (n); types of participants</th>
<th>Objective</th>
<th>Efficacy outcomes and main results</th>
<th>Conclusions and limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen (2010)(^{10}) 10 RCTs n=2769 (4062 attacks)</td>
<td>To determine efficacy and tolerability of acetaminophen, alone or in combination with antiemetic, compared to placebo or other active interventions in treatment of acute migraine in adults</td>
<td>Primary efficacy outcomes: pain-free at 2 h, without use of rescue medications; headache relief at 1 h &amp; 2 h; sustained pain-free** over 24 h; sustained pain reduction*** over 24 h</td>
<td>Acetaminophen 1,000 mg alone is an effective treatment for acute migraine headaches; the addition of metoclopramide 10 mg gives short-term efficacy equivalent to oral sumatriptan 100 mg. AE s with acetaminophen did not differ from placebo; &quot;major&quot; AEs were slightly more common with sumatriptan than with acetaminophen + metoclopramide. Note: potential for hepatotoxicity with acetaminophen</td>
</tr>
<tr>
<td>Types of participants: adults (≥ 18 years); IHS criteria for migraine diagnosis; stable prophylactic therapy allowed</td>
<td>Main results: Acetaminophen 1,000 mg vs. placebo: 2-h pain-free: 19% vs. 10% (NNT=12) 1-h headache relief: 39% vs. 20% (NNT=5.2) 2-h headache relief: 56% vs. 36% (NNT=5) Nausea phophonphia &amp; phophonphia reduced more with acetaminophen vs. placebo at 2 h (NNTs of 7-11); more individuals were free of functional disability at 2 h with acetaminophen (NNT=10) &amp; fewer needed rescue medication over 6 h (NNT=6) Acetaminophen 1,000 mg + metoclopramide 10 mg vs. sumatriptan 100 mg: 2-h headache relief: 39% vs. 42% (NS; NNT not calculated); no 2-pain-free data; NS difference in relief of phophophobia &amp; phophonphia at 2h) AE rates similar for acetaminophen vs. placebo, and between acetaminophen + metoclopramide &amp; sumatriptan; more &quot;major&quot; adverse events occurred with sumatriptan (NNT=32)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ibuprofen (2007)(^{55}) 5 RCTs n=1353 (pain relief) n=2161 (pain-free)</td>
<td>To evaluate efficacy of low-dose ibuprofen (200 or 400 mg) for treatment of acute migraine attack</td>
<td>Primary efficacy outcomes: pain-free at 2 h without use of rescue medications; headache relief at 1 h &amp; 2 h; sustained pain-free** over 24 h; sustained pain reduction*** over 24 h</td>
<td>Ibuprofen (200 &amp; 400 mg) is effective in reducing headache intensity &amp; rendering adult patients pain-free at 2 h; phophophobia &amp; phophonphia improved with 400 mg dose only. AE s were similar for ibuprofen &amp; placebo.</td>
</tr>
<tr>
<td>Types of participants: age ≥ 16 years, moderate or severe migraine attacks</td>
<td>Main results: Ibuprofen 400 mg vs. placebo: 2-h pain-free (26% vs. 12%): NNT=7.2 2-h headache relief (57% vs. 25%): NNT=3.2 24-h sustained headache relief (45% vs. 19%): NNT=4.0 Ibuprofen 200 mg vs. placebo: 2-h pain-free (20% vs. 10%): NNT=9.7 2-h headache relief (52% vs. 37%): NNT=6.3 Ibuprofen 400 mg solubilized vs. standard tablets (no head-to-head trials): 1-h headache relief: NNT=1.9 vs. NNT=8.3 (p=0.0114) 2-h headache relief: NS difference</td>
<td>Ibuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority; NNT for ibuprofen 400 mg significantly superior to 200 mg for 2-h pain relief only. Results are similar to those for ASA 900 mg or 1000 mg, with ibuprofen 400 mg performing slightly better than ASA, and ibuprofen 200 mg slightly worse [see ASA a antiemtic (2010) below]. Solubilized formulations (e.g., liquid) were superior for 1-h but not 2-h headache relief vs. standard tablets. AE s were mostly mild and transient with ibuprofen.</td>
<td></td>
</tr>
<tr>
<td>Types of participants: adults (≥ 18 years); IHS criteria for migraine diagnosis; stable prophylactic therapy allowed</td>
<td>Ibuprofen (200 mg) is effective in reducing headache intensity &amp; rendering adult patients pain-free at 2 h; phophophobia &amp; phophonphia improved with 400 mg dose only. AE s were similar for ibuprofen &amp; placebo.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Types of participants: adults (≥ 18 years); IHS criteria for migraine diagnosis; stable prophylactic therapy allowed</td>
<td>Ibuprofen (200 mg) is effective in reducing headache intensity &amp; rendering adult patients pain-free at 2 h; phophophobia &amp; phophonphia improved with 400 mg dose only. AE s were similar for ibuprofen &amp; placebo.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naproxen Sodium (2010)(^{55}) 4 RCTs n=2168</td>
<td>To assess efficacy &amp; safety of naproxen sodium in treatment of acute migraine attacks</td>
<td>Primary efficacy outcomes: pain-free at 2 h without use of rescue medications; headache relief at 1 h &amp; 2 h; sustained pain-free** over 24 h; sustained pain reduction*** over 24 h</td>
<td>Naproxen sodium is more effective but may cause more adverse events than placebo in moderate to severe migraine; it is effective in reducing headache intensity, rendering pain-free at 2 h &amp; improving migraine-associated symptoms.</td>
</tr>
<tr>
<td>Types of participants: adults; moderate to severe attacks</td>
<td>Main results: Naproxen sodium 1,000 mg vs. placebo: 2-h pain-free: 44% vs. 32% (NNT=4.5); 1-h headache relief: 62% vs. 55% (NNT=1.8) No significant difference in headache recurrence between naproxen sodium &amp; placebo</td>
<td>Naproxen sodium was more effective than placebo: pooled risk ratios were 1.58 (95% CI 1.41-1.77, p=0.00002), and 2.22 (95% CI 1.46-3.37, p=0.00002), respectively, for headache relief at 2 h and pain-free at 2 h</td>
<td>Naproxen sodium was more effective but may cause more adverse events than placebo in moderate to severe migraine; it is effective in reducing headache intensity, rendering pain-free at 2 h &amp; improving migraine-associated symptoms.</td>
</tr>
<tr>
<td>ASA ± antiemetic (metoclopramide) (2010)(^{9}) 13 RCTs n=4222 (treating 526 migraine headaches of moderate to severe intensity)</td>
<td>To determine efficacy &amp; tolerability of ASA (900 or 1,100 mg), alone or in combination with metoclopramide (10 mg), compared to placebo &amp; other active comparators (sumatriptan) in treatment of acute migraine headaches in adults</td>
<td>Primary efficacy outcomes: pain-free at 2 h, without use of rescue medications; headache relief at 1 h &amp; 2 h; sustained pain-free** over 24 h; sustained pain reduction*** over 24 h</td>
<td>ASA 1,000 mg is an effective treatment for acute migraine headaches, similar to sumatriptan 50 or 100 mg, with reduction in both pain &amp; associated symptoms such as nausea &amp; phophonphia; addition of metoclopramide 10 mg improves relief of nausea &amp; vomiting; sumatriptan 100 mg was superior to ASA/metoclopramide for pain-free at 2 h. AE s mainly mild &amp; transient, &amp; slightly more common with ASA than placebo, but less common than with sumatriptan 100 mg. Further studies are needed to establish efficacy of ASA compared to other triptans &amp; NSAIDs.</td>
</tr>
<tr>
<td>Types of participants: adults (≥ 18 years); IHS criteria for migraine diagnosis; stable prophylactic therapy allowed</td>
<td>Main results: ASA 900 mg vs. placebo: 2-h pain-free: 25% vs. 12% (NNT=8.1) 2-h headache relief: 52% vs. 32% (NNT=4.9) 24-h sustained headache relief: 39% vs. 24% (NNT=6.6) ASA 900 mg ± metoclopramide 10 mg vs. placebo: 2-h pain-free: 18% vs. 7% (NNT=8.7) 2-h headache relief: 57% vs. 26% (NNT=3.3) 24-h sustained headache relief: 37% vs. 17% (NNT=6.2) No data for 24-h sustained pain-free Sumatriptan 50 mg did not differ from ASA alone for 2-h pain-free and headache relief, while sumatriptan 100 mg was better than ASA ± metoclopramide for 2-h pain-free (but not headache relief); there was no data for 24-h headache relief</td>
<td>ASA 1,000 mg is an effective treatment for acute migraine headaches, similar to sumatriptan 50 or 100 mg, with reduction in both pain &amp; associated symptoms such as nausea &amp; phophonphia; addition of metoclopramide 10 mg improves relief of nausea &amp; vomiting; sumatriptan 100 mg was superior to ASA/metoclopramide for pain-free at 2 h.</td>
<td></td>
</tr>
</tbody>
</table>
Table 7: Meta-analyses/systematic reviews of acetaminophen, ASA and NSAIDs for acute migraine treatment [part 2] continued

<table>
<thead>
<tr>
<th>Drug</th>
<th>RCTs (individual patient data meta-analysis)</th>
<th>Types of participants: adults (≥18 years); IHS criteria for migraine diagnosis: history of migraine at least 1 year; headache attacks per month</th>
<th>Efficacy &amp; safety outcomes</th>
<th>Adverse events outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASA effervescent</strong> (eASA)</td>
<td>(2007)**</td>
<td>To evaluate efficacy &amp; safety of ASA 1,000 mg in comparison with placebo</td>
<td>Pain (i.e., headache) relief at 2 h: eASA: 51.5% (95% CI: 46.6-56.5%)</td>
<td>EAs mostly mild &amp; transient, occurring slightly more often with ASA vs. placebo</td>
</tr>
<tr>
<td><strong>Diclofenac potassium</strong></td>
<td>(2012)**</td>
<td>To determine efficacy &amp; tolerability of diclofenac alone or in combination with an antiemetic, compared to placebo and other active interventions in treatment of acute migraine headaches in adults</td>
<td>Primary efficacy outcomes: pain-free at 1 h &amp; 2 h, without use of rescue medication; headache relief* at 1 h &amp; 2 h; sustained pain-free** during 24 h post-dose (pain-free at 2 h) &amp; no use of rescue medication or recurrence of moderate to severe pain within 24 h; sustained headache relief*** during 24 h post-dose</td>
<td>Schwartz et al., 2012: Oral diclofenac potassium 50 mg is an effective treatment for acute migraine, providing relief from pain and associated symptoms; only a minority of patients achieved pain-free responses.</td>
</tr>
</tbody>
</table>

---

*Headache relief: pain reduced from moderate to severe or none to mild, without use of rescue medication. **Sustained pain-free for 24 h: pain-free within 2 h, with no use of rescue medication and recurrence within 24 h. ***Sustained pain reduction/headache relief for 24 h: headache relief at 2 h, sustained for 24 h, with no use of rescue medication or a second dose of study medication. RCTs = randomized, controlled trials; IHS = International Headache Society; NNT = number-needed-to-treat; NNH = number-needed-to-harm; NS = non-statistically significant; AEs = adverse events; CI = confidence interval

---

**Efficacy & safety outcomes**

- Pain reduction at 2 h: eASA: 51.5% (95% CI: 46.6-56.5%) vs. placebo: 33.9% (95% CI: 29.1-38.6%)
- Pain-free at 2 h: eASA: 27.1% (95% CI: 22.6-31.4%) vs. placebo: 15.1% (95% CI: 11.5-18.7%)
- Sustained pain-free up to 24 h: eASA: 23.5% (95% CI: 19.3-27.7%) vs. placebo: 14.6% (95% CI: 11.0-18.1%)
- Lower frequency of AEs (including gastrointestinal) in eASA vs. sumatriptan group (12.0% vs. 16.2%)

---

**Adverse events outcomes**

- No statistically significant difference between either dose of diclofenac potassium & sumatriptan 100 mg. AEs mostly mild to moderate and transient with diclofenac potassium; same rate as placebo.

---

**Recommendations (adjunctive drugs)**

1. **Strong recommendation, moderate quality evidence:** Metoclopramide (10 mg orally) is recommended for use with acute migraine medications for migraine attacks to improve relief of nausea.
2. **Strong recommendation, low quality evidence:** Domperidone (10 mg orally) is recommended for use with acute migraine medications for migraine attacks to improve relief of nausea.

---

**Conclusions**

In this targeted review, strong recommendations for use in acute migraine therapy have been made for 7 triptans, 4 NSAIDs (including ASA), and acetaminophen. All of these had high quality evidence supporting their use. Another medication, dihydroergotamine (intranasal or SC self-injection), received a weak recommendation for use related to the balance between efficacy and side effects, based on moderate quality evidence. Three other medications, all of which were not recommended for routine use, received weak recommendations for use.
ergotamine, codeine-containing combination analgesics, and tramadol-containing analgesics. Supporting evidence for use for these three medications ranged from low to moderate quality evidence.

Two anti-emetics, metoclopramide and domperidone, received strong recommendations for use, with moderate quality evidence for metoclopramide and low quality evidence for domperidone.

Two medications received strong “do not use” recommendation (except for use in exceptional circumstances): butalbital-containing medications and butorphanol (intranasal), supported by low quality evidence. The above recommendations are summarized in Table 8.

Choice of an acute medication for a specific patient must be individualized, based on evidence for efficacy, potential drug side effects, co-existent medical and psychiatric illnesses, and patient preference. It also needs to be recognized that patient response to acute migraine medications is idiosyncratic and often cannot be predicted in advance. Therefore, multiple treatment options may need to be tried before an excellent medication for the patient is found.

Patient preference may also include considerations of cost, and cost may be a societal consideration as well. However, it must be kept in mind that most of the costs associated with migraine are indirect costs related to missed work and other activities, and these are often much larger than the direct costs which include medication costs.

The principles of acute migraine therapy are discussed further in Section 1 of this guideline, and acute medication choice for individual patients is discussed in greater detail in Section 3.

**REFERENCES**


